<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63642</article-id><article-id pub-id-type="doi">10.7554/eLife.63642</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Microbial genetic and transcriptional contributions to oxalate degradation by the gut microbiota in health and disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-210935"><name><surname>Liu</surname><given-names>Menghan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9390-8194</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" id="author-210936"><name><surname>Devlin</surname><given-names>Joseph C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210937"><name><surname>Hu</surname><given-names>Jiyuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210938"><name><surname>Volkova</surname><given-names>Angelina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112700"><name><surname>Battaglia</surname><given-names>Thomas W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210943"><name><surname>Ho</surname><given-names>Melody</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210944"><name><surname>Asplin</surname><given-names>John R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-210939"><name><surname>Byrd</surname><given-names>Allyson</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-210940"><name><surname>Loke</surname><given-names>P'ng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6211-3292</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210941"><name><surname>Li</surname><given-names>Huilin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210942"><name><surname>Ruggles</surname><given-names>Kelly V</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0152-0863</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-128707"><name><surname>Tsirigos</surname><given-names>Aristotelis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-138042"><name><surname>Blaser</surname><given-names>Martin J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2447-2443</contrib-id><email>martin.blaser@cabm.rutgers.edu</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-210945"><name><surname>Nazzal</surname><given-names>Lama</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0106-5060</contrib-id><email>Lama.Nazzal@nyulangone.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>NYU Langone Health</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Vilcek Institute of Graduate Biomedical Sciences</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Litholink Corporation, Laboratory Corporation of America Holdings</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Cancer Immunology, Genentech Inc</institution><addr-line><named-content content-type="city">South San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Center for Advanced Biotechnology and Medicine, Rutgers University</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Garrett</surname><given-names>Wendy S</given-names></name><role>Senior Editor</role><aff><institution>Harvard T.H. Chan School of Public Health</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Turnbaugh</surname><given-names>Peter</given-names></name><role>Reviewing Editor</role><aff><institution>University of California, San Francisco</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Department of Biological Sciences, Columbia University, New York, United States</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>26</day><month>03</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e63642</elocation-id><history><date date-type="received" iso-8601-date="2020-10-01"><day>01</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-03-23"><day>23</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Liu et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Liu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63642-v2.pdf"/><abstract><p>Over-accumulation of oxalate in humans may lead to nephrolithiasis and nephrocalcinosis. Humans lack endogenous oxalate degradation pathways (ODP), but intestinal microbes can degrade oxalate using multiple ODPs and protect against its absorption. The exact oxalate-degrading taxa in the human microbiota and their ODP have not been described. We leverage multi-omics data (&gt;3000 samples from &gt;1000 subjects) to show that the human microbiota primarily uses the type II ODP, rather than type I. Furthermore, among the diverse ODP-encoding microbes, an oxalate autotroph, <italic>Oxalobacter formigenes</italic>, dominates this function transcriptionally. Patients with inflammatory bowel disease (IBD) frequently suffer from disrupted oxalate homeostasis and calcium oxalate nephrolithiasis. We show that the enteric oxalate level is elevated in IBD patients, with highest levels in Crohn’s disease (CD) patients with both ileal and colonic involvement consistent with known nephrolithiasis risk. We show that the microbiota ODP expression is reduced in IBD patients, which may contribute to the disrupted oxalate homeostasis. The specific changes in ODP expression by several important taxa suggest that they play distinct roles in IBD-induced nephrolithiasis risk. Lastly, we colonize mice that are maintained in the gnotobiotic facility with <italic>O. formigenes</italic>, using either a laboratory isolate or an isolate we cultured from human stools, and observed a significant reduction in host fecal and urine oxalate levels, supporting our in silico prediction of the importance of the microbiome, particularly <italic>O. formigenes</italic> in host oxalate homeostasis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>microbiota</kwd><kwd>oxalate metabolism</kwd><kwd>metatranscriptome</kwd><kwd>metagenome</kwd><kwd>IBD</kwd><kwd>gene expressions</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases (NIAID)</institution></institution-wrap></funding-source><award-id>U01AI22285</award-id><principal-award-recipient><name><surname>Blaser</surname><given-names>Martin J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</institution></institution-wrap></funding-source><award-id>R01DK110014</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Huilin</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Rare Kidney Stone Consortium</institution></institution-wrap></funding-source><award-id>U54 DK083908</award-id><principal-award-recipient><name><surname>Nazzal</surname><given-names>Lama</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>The C &amp; D and Zlinkoff Funds</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Blaser</surname><given-names>Martin J</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009579</institution-id><institution>Oxalosis and Hyperoxaluria Foundation</institution></institution-wrap></funding-source><award-id>career development grant</award-id><principal-award-recipient><name><surname>Nazzal</surname><given-names>Lama</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>TransAtlantic Partnership of the Fondation LeDucq</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Blaser</surname><given-names>Martin J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel multi-omics framework revealed the taxonomic contribution to microbiota oxalate, demontrated <italic>O. formigenes</italic> as the dominating taxon transcriptionally, and identified specific IBD cohort at risk for oxalte toxicity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Over-accumulation of oxalate in humans leads to toxicity (<xref ref-type="bibr" rid="bib9">Asplin et al., 1998</xref>; <xref ref-type="bibr" rid="bib13">Beck et al., 2013</xref>). The most common oxalate toxicity is calcium oxalate nephrolithiasis, which accounts for more than 70% of overall nephrolithiasis, affecting 9% of the US population with a 20% 5-year recurrence rate (<xref ref-type="bibr" rid="bib63">Lieske et al., 2014</xref>; <xref ref-type="bibr" rid="bib84">Rule et al., 2014</xref>; <xref ref-type="bibr" rid="bib85">Saran et al., 2018</xref>; <xref ref-type="bibr" rid="bib88">Scales et al., 2012</xref>; <xref ref-type="bibr" rid="bib90">Stamatelou et al., 2003</xref>). Oxalate toxicity can also induce chronic kidney disease, an illness affecting more than 30 million Americans, via multiple mechanisms including the activation of the NALP3 inflammasome pathway (<xref ref-type="bibr" rid="bib54">Knauf et al., 2013</xref>; <xref ref-type="bibr" rid="bib77">Mulay et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Mulay et al., 2013</xref>; <xref ref-type="bibr" rid="bib85">Saran et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Waikar et al., 2019</xref>), RIPK3-MLKL-mediated necroptosis (<xref ref-type="bibr" rid="bib75">Mulay et al., 2016a</xref>), and oxidative stress-induced cell injury (<xref ref-type="bibr" rid="bib50">Khan et al., 2006</xref>). In extreme cases, life-threatening systemic oxalosis occurs.</p><p>Humans lack endogenous oxalate-degrading enzymes. By contrast, the mammalian intestinal microbes can degrade oxalate, partially protecting their hosts against toxicity (<xref ref-type="bibr" rid="bib6">Allison and Cook, 1981</xref>; <xref ref-type="bibr" rid="bib5">Allison et al., 1986</xref>; <xref ref-type="bibr" rid="bib3">Allison et al., 1977</xref>; <xref ref-type="bibr" rid="bib11">Barber and Gallimore, 1940</xref>; <xref ref-type="bibr" rid="bib70">Miller et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Azcarate-Peril et al., 2006</xref>) <italic>Oxalobacter formigenes</italic>,Lactobacillus sp., Bifidobacterium sp., Enterobacteriaceae, and others can degrade oxalate in vitro (<xref ref-type="bibr" rid="bib73">Mogna et al., 2014</xref>), and colonization with these taxa in rodent hyperoxaluria models showed reduction in urinary oxalate indicating oxalate degradation in vivo (<xref ref-type="bibr" rid="bib40">Hatch et al., 2006</xref>; <xref ref-type="bibr" rid="bib52">Klimesova et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Kwak et al., 2006</xref>). Of these oxalate degraders, only <italic>O. formigenes</italic> is a specialist that uses oxalate as its sole energy source (<xref ref-type="bibr" rid="bib21">Cornick and Allison, 1996</xref>). <italic>O. formigenes</italic> also is unique because it induces host oxalate secretion into the colonic lumen (<xref ref-type="bibr" rid="bib8">Arvans et al., 2017</xref>).</p><p>The oxalate-degrading microbes in the human microbiota in vivo have not been characterized. Previous studies on oxalate-degrading microbes have been chiefly done in vitro or in animal models, and the relevance of those microbes to human health remains undefined (<xref ref-type="bibr" rid="bib32">Fontenot et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Klimesova et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Kullin et al., 2014</xref>; <xref ref-type="bibr" rid="bib97">Turroni et al., 2010</xref>; <xref ref-type="bibr" rid="bib96">Turroni et al., 2007</xref>). This gap limits our understanding of the role of microbiota in diseases induced by oxalate toxicity. Here, we leveraged multi-omics data of the healthy human microbiome to characterize the oxalate-degrading microbes in vivo.</p><p>Inflammatory bowel disease (IBD) patients are at increased risk for oxalate toxicity, due to a condition called enteric hyperoxaluria (EH). In EH, enhanced bioavailability and hyperabsorption of intestinal oxalate result in oxalate nephrolithiasis (<xref ref-type="bibr" rid="bib20">Corica and Romano, 2016</xref>; <xref ref-type="bibr" rid="bib65">Liu and Nazzal, 2019</xref>). In the USA, &gt;50,000 IBD patients suffer from EH and recurrent calcium oxalate kidney stones (<xref ref-type="bibr" rid="bib20">Corica and Romano, 2016</xref>; <xref ref-type="bibr" rid="bib68">McConnell et al., 2002</xref>). EH in IBD patients may reflect lipid malabsorption and increased gut permeability. However, an alternate hypothesis is that microbiota-based oxalate degradation is impaired in dysbiotic IBD patients, leading to increased oxalate absorption (<xref ref-type="bibr" rid="bib5">Allison et al., 1986</xref>). We interrogated the microbiota of IBD patients to understand shifts in microbiota-based oxalate degradation functions and their metabolic consequences.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Type I and type II microbial oxalate degradation pathways</title><p>To determine the oxalate degradation pathways (ODPs) used by human gut bacteria, we curated all experimentally validated microbial ODP from literature review and database searches (see Materials and methods) (<xref ref-type="bibr" rid="bib4">Allison et al., 1985</xref>; <xref ref-type="bibr" rid="bib7">Anand et al., 2002</xref>; <xref ref-type="bibr" rid="bib15">Blackmore and Quayle, 1970</xref>; <xref ref-type="bibr" rid="bib24">Daniel et al., 2004</xref>; <xref ref-type="bibr" rid="bib25">Dumas et al., 1993</xref>; <xref ref-type="bibr" rid="bib33">Foster et al., 2012</xref>; <xref ref-type="bibr" rid="bib83">Pierce et al., 2010</xref>). We classified those ODPs into two types based on their enzymatic mechanisms and co-factor requirements. Type I ODPs cleave the oxalate carbon-carbon (C-C) bond in a single step (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The two recognized type I enzymes, oxalate oxidase and oxalate decarboxylase, are indistinguishable at the amino acid level; therefore, we refer to them jointly as oxalate oxidase/decarboxylase (OXDD) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Type II ODPs consists of two enzymatic reactions requiring coenzyme A as co-factor (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). First, a coenzyme A molecule is added to oxalate to form oxalyl-CoA via enzymes including formyl-CoA transferase (FRC) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In the second step, oxalyl-CoA decarboxylase (OXC) metabolizes oxalyl-CoA into CO<sub>2</sub> and formyl-CoA (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Type I and type II microbial oxalate-degrading pathway (ODP).</title><p>(<bold>A</bold>) Schema of type I and type II ODP. Enzymes are annotated with corresponding KEGG IDs. OXDD, FRC, and OXC are the focus of the present study. (<bold>B</bold>). Cladogram of microbial genera that encode oxalate-degrading enzymes OXDD, FRC, and OXC. The three rings surrounding the cladogram indicate OXDD-, FRC-, or OXC-encoding genera, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Inter-class and intra-class ODE protein identity associated with each microbial class.</title><p>Panels focus on OXDD (<bold>A</bold>), OXC (<bold>B</bold>), or FRC (<bold>C</bold>). The pairwise identity between any two protein homologs was calculated based on the multiple alignments using amino acid sequences, by <xref ref-type="bibr" rid="bib31">Fitch, 1966</xref> or identity distance matrix (see Materials and methods for details). The number of ODE homologs available for each class is indicated in parenthesis. Classes with &gt;20 ODE are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Knowing the relevant oxalate degradation enzymes (ODEs), we then acquired all available protein homologs of the three ODE OXDD (n = 2836), FRC (n = 1947), and OXC (n = 1284), which enable homology search from UniProt Interpro (<xref ref-type="bibr" rid="bib71">Mitchell et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">Mulder et al., 2005</xref>). By tracing the taxonomic origin of the genes encoding those homologs, we found that OXDD-coding taxa can be fungal or bacterial, whereas FRC- and OXC-coding taxa are strictly bacterial (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The frequent co-occurrence of FRC and OXC in individual genomes indicates encoding complete type II ODP (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). As expected, OXDD, FRC, and OXC each are conserved within the same microbial class, but exhibit substantial divergence across classes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). These data provide both a comprehensive inventory of ODPs and a reference set of ODP-encoding microbes, which enable analyses to elucidate those relevant to humans.</p></sec><sec id="s2-2"><title>ODPs utilized by the gut microbiota of healthy humans</title><p>Next, we asked whether those ODPs are encoded or expressed by microbes within the intestinal tract of healthy humans. To do so, we computationally examined the presence of the ODE within the gut metagenome and metatranscriptome from publicly available samples of healthy humans. From five studies, we analyzed a total of 2359 metagenome and 1053 transcriptome samples from 660 and 165 healthy individuals, respectively (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). After quality-filtering (see Materials and methods), the sequencing reads were aligned to the unique OXDD, FRC, and OXC homologous proteins we had identified, using DIAMOND Blastx (<xref ref-type="bibr" rid="bib16">Buchfink et al., 2015</xref>). Alignment pairs with &gt;90% identity were retained for downstream analyses. The alignment cutoff was based on the protein identity of the inter- and intra-species ODEs and determined to be robust for distinguishing ODEs originating from differing microbial species (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>We found that the majority of the healthy gut microbiomes include ODEs with at least one ODE detected in the metagenome of 607 (92%) of 660 subjects and the metatranscriptome of 132 (80%) of 165 subjects. In the metagenomes, the type II <italic>frc</italic> and <italic>oxc</italic> genes were more common (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) and more abundant (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) than the type I <italic>oxdd</italic> gene. Similarly, in metatranscriptomes, expressions of type II genes were more common and abundant (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>). Expression of <italic>oxdd</italic> was only detected in 10 (6%) of the 165 subjects, and the median RPKM was 2-log<sub>10</sub> lower than those of <italic>frc</italic> or <italic>oxc</italic> (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>). Furthermore, <italic>frc</italic> and <italic>oxc</italic> – the coding genes of the two enzymes that catalyze the separate steps in type II PDP – were frequently co-expressed within the same microbiota, indicating expression of the complete type II ODPs (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Detection of type I and II ODE within the fecal metagenome and metatranscriptome of 660 and 165 healthy human subjects.</title><p>Prevalence (<bold>A</bold>) and abundance (<bold>B</bold>) of ODE in the fecal metagenome of five studies surveyed. Numbers written on the bottom bars indicate the numbers of subjects in whom the corresponding ODE is detected, and only those subjects were considered in (<bold>B</bold>). Prevalence (<bold>C</bold>) and abundance (<bold>D</bold>) of OXDD, FRC, and OXC in the fecal metatranscriptome of four studies surveyed. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, by proportion tests for (<bold>A</bold>) and (<bold>C</bold>), by multiple-adjusted Mann–Whitney tests for (<bold>B</bold>) and (<bold>C</bold>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Detection of OXDD, FRC, and OXC in the metagenome and metatranscriptome of healthy individuals.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63642-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Beta-diversity of metabolic profiles associated with the metagenomic and metatranscriptomic samples from healthy human subjects, ordinated on a Tsne (t-distributed stochastic neighbor embedding) plot.</title><p>The metabolic profile is assessed by the HUMAnN2 (<xref ref-type="bibr" rid="bib35">Franzosa et al., 2018</xref>) pipeline using (see Materials and methods). The metabolic profiles for each subject are calculated by taking the mean measurements provided. The table shows the number of subjects who provided metagenomic (MTG ●) and metatranscriptomic (MTS ▲) data. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref> for study information.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>The protein identity between inter-species and intra-species ODEs, for each microbial genus.</title><p>Panels focus on OXDD (<bold>A</bold>), OXC (<bold>B</bold>), or FRC (<bold>C</bold>). The pairwise protein identities were calculated based on amino acid sequence alignment (see Materials and methods for details). The number of ODE homologs available for each genus is indicated in parenthesis. The blastx identity cutoff 90% used in this study is indicated by the dashed line. Genera with &gt;20 ODE homologs and genus Oxalobacter are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Co-detection of OXDD, FRC, and OXC in the metatranscriptomes of subjects across different studies.</title><p>Subjects with at least one ODE detected in the metatranscriptome are shown, with percent of total subjects displayed in panels, for each study, indicated in parentheses.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig2-figsupp3-v2.tif"/></fig></fig-group><p>These data indicate that microbes utilizing type II rather than type I ODPs predominate in the human intestine. Such finding is consistent in all studies, despite the differences in source populations and sample preparation methods (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). For the remaining analyses, we focused on the type II ODPs.</p></sec><sec id="s2-3"><title>Microbial species that transcribe the type II ODPs in vivo</title><p>Although multiple human commensal microbes are known to encode <italic>frc</italic> and <italic>oxc</italic>, whether they transcribe those genes in vivo has not been studied (<xref ref-type="bibr" rid="bib1">Abratt and Reid, 2010</xref>; <xref ref-type="bibr" rid="bib19">Cho et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Fontenot et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Mogna et al., 2014</xref>). We next characterized the microbial species transcribing these type II ODP genes in the microbiota of healthy humans. In the metagenomes of 660 individuals, <italic>oxc</italic> gene of multiple species, including <italic>Escherichia coli</italic>, <italic>O. formigenes</italic>, and several Muribaculaceae, Bifidobacterium, and Lactobacillus sp., was detected (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, left); <italic>E. coli oxc</italic> was the most common (56% of subjects), followed by <italic>O. formigene</italic>s <italic>oxc</italic> (39% of subjects).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Expression of type II ODP of microbial species within the intestinal microbiota of healthy humans.</title><p>(<bold>A</bold>) Abundance and prevalence of OXC of microbial species in the metagenome (left) or metatranscriptome (right) of 660 and 165 subjects. Box plots indicate the abundance of microbial OXC (log<sub>10</sub> RPKM) among subjects in whom OXC is detected, and are generated with <italic>ggplot2</italic> with outliers excluded. Bar plots indicate the prevalence of microbial oxc, with percentage annotated. Microbial species are ordered by the corresponding metagenomic OXC prevalence. A parallel analysis for FRC is shown in <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5</xref>. (<bold>B</bold>) Detection of OXC and FRC of microbial species in the subject-matched metagenome and metatranscriptome, by study. For each microbial ODE, the subjects are divided into four groups (shown in different colors) based on the co-detection of ODE in the matched metagenome and metatranscriptome, with percent (%) of which reflected. The fran Study, from which <italic>E. coli</italic> ODP was detected in all subjects, used a sample extraction method known to induce <italic>E. coli</italic>, as noted in their publication (<xref ref-type="bibr" rid="bib34">Franzosa et al., 2014</xref>). (<bold>C</bold>) Population-level contribution of individual species to metagenomic (left) or metatranscriptomic (right) OXC. The population-level contribution of each species was calculated at a relative scale (see Materials and methods) and plotted. Raw values can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>. The 10 species that have the highest metagenomic or metatranscriptomic contribution are shown. A parallel analysis for FRC is shown in <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Species contribution to FRC, and OXC in the metagenome and metatranscriptome of healthy individuals.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63642-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Detection of OXC of microbial species in the microbiome of healthy human subjects from US_men (<bold>A</bold>), HMP2 (<bold>B</bold>), AMP (<bold>C</bold>), or fran (<bold>D</bold>) study.</title><p>Left and right panels focus on detection in metagenomic and metatranscriptomic data, respectively. (Follows legend of <xref ref-type="fig" rid="fig3">Figure 3A</xref>.)</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Tsne plot of 594 metagenomic and 131 metatranscriptomic samples, based on the abundances OXC and FRC.</title><p>OXC and FRC of microbes in <xref ref-type="fig" rid="fig3">Figures 3A</xref> and <xref ref-type="fig" rid="fig5">5</xref> were used. Tsne is calculated with <italic>Rtsne v0.15</italic> package in R. The OXC- and FRC-specific study effects are not significant, examined using PERMANOVA using 1000 permutations (p&gt;0.1).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Detection of FRC of microbial species in the metagenome (left) or metatranscriptome (right) of healthy human subjects.</title><p>(Follows the legend for <xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Population-level contribution of individual species to metagenomic (left) or metatranscriptomic (right) FRC.</title><p>Follows the legend for <xref ref-type="fig" rid="fig3">Figure 3D</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig3-figsupp4-v2.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 5.</label><caption><title>Detection of ODE using ShortBRED.</title><p>(<bold>A</bold>) Comparison of ODE detection using ShortBred and using Diamond in all samples (n = 5557) included in this present study. Each point represents the total abundance of FRC, OXC, or OXDD homologs in one individual. Mean measurements were used for study subjects who provided multiple samples. Statistics were generated using Spearman correlations. (<bold>B</bold>). Abundance and prevalence of FRC of microbial species in the metagenome (left) or metatranscriptome (right) of 660 and 165 subjects. Detection of FRC and OXC protein families by ShortBRED using default parameters. The text on the left indicates the centroid protein for each protein homolog. (<bold>B</bold>) FRC: All three <italic>O. formigenes</italic> FRCs (C3 × 9Y2, C3 × 762, and C3 × 2D4) are in a protein family that contains only that one enzyme (See New Supplement File 1 for the clustering centroid-member map). (<bold>C</bold>) OXC. Unlike results for FRC, no <italic>O. formigenes</italic> OXC homologs were detected.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig3-figsupp5-v2.tif"/></fig><fig id="fig3s6" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 6.</label><caption><title>Detection of <italic>O. formigenes</italic> OXC using merged long marker peptides identified by ShortBRED.</title><p>(<bold>A</bold>) Multiple alignment of 5 and the marker peptides. A total of 20 marker peptides (Marker_#1 - Marker_#20) with 16.5 amino acid (AA) median length were identified by <italic>ShortBRED-identify</italic> using default parameters. Peptides one AA apart were further merged (including the gap AA) into four long marker peptides #21–#24 with median length of 48.5 AA. (<bold>B,C</bold>) Prevalence (% subject positive) (<bold>B</bold>) and abundance (<bold>C</bold>) of merged marker peptides in metatranscriptomes, detected by ShortBRED. The shortest Marker #23 (17 AA) is not detected in any sample. Statistics were done compared to Healthy subjects as the reference for proportion tests (<bold>B</bold>) and Wilcoxon rank tests (<bold>C</bold>) with adjustment for multiple comparisons.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig3-figsupp6-v2.tif"/></fig></fig-group><p>In the metatranscriptomes of 167 individuals, <italic>oxc</italic> gene expression did not directly correlate with corresponding gene abundance or prevalence (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, right). <italic>O. formigenes oxc</italic> expression was both most abundant and most prevalent (in 61% of subjects) in the metatranscriptomes (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, right). Despite the detection of <italic>E. coli oxc</italic> in 56% of subjects, its transcript was present in only 12% of the subjects (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). For Bifidobacterium and Lactobacillus species, for which oxalate degradation activity was reported in vitro and in animal models (<xref ref-type="bibr" rid="bib30">Federici et al., 2004</xref>; <xref ref-type="bibr" rid="bib52">Klimesova et al., 2015</xref>; <xref ref-type="bibr" rid="bib97">Turroni et al., 2010</xref>), <italic>oxc</italic> expression was minimal (&lt;5%) or not prevalent (<xref ref-type="fig" rid="fig3">Figure 3A</xref> right). The dichotomy between metagenomic and metatranscriptomic <italic>oxc</italic> was consistent across different studies (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>), and also present for the other type II ODP gene <italic>frc</italic> (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>).</p><p>To more rigorously examine ODP expression by individual taxa, we further co-analyzed the presence of ODP genes and transcripts matched by subject (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). <italic>O. formigenes frc</italic> and <italic>oxc</italic> were transcribed in nearly all subjects in whom the genes were detected, as well as in others in whom the gene was not detected, indicating that their expression is common in vivo (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The under-detection of <italic>O. formigenes</italic> ODP genes in the metagenomes may reflect the highly variable abundance of the organism, often below the lower detection limit using gene-based methods (<xref ref-type="bibr" rid="bib12">Barnett et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Guo et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Kelly et al., 2011</xref>; <xref ref-type="bibr" rid="bib80">PeBenito et al., 2019</xref>). In contrast, <italic>E. coli frc</italic> and <italic>oxc</italic> were expressed in only a few subjects even when the corresponding genes were detected metagenomically (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). These data indicate that in vivo <italic>E. coli</italic> rarely transcribe ODP, a pathway used for defense against oxalate-induced stress (<xref ref-type="bibr" rid="bib32">Fontenot et al., 2013</xref>). In total, these findings demonstrate that ODP transcription varies widely in individual hosts, and by species.</p></sec><sec id="s2-4"><title>The contributions of individual species to the global microbiota ODP</title><p>We then assessed the impact of individual species on global ODP by quantifying their population-level contributions (see Materials and methods). The contribution of <italic>O. formigenes</italic> to ODP increased from 17% to 63% from the metagenomic to the metatranscriptomic level, greater than the transcriptomic contributions of all other species combined (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). Conversely, the <italic>E. coli</italic> contribution to ODP was markedly reduced from the metagenomic (36%) to the metatranscriptomic (7%) level (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Other species had low but varied contributions (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). A parallel pattern was observed for <italic>frc</italic> (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). With the low activity of non-<italic>O. formigenes</italic> species, network analysis did not yield significant species-species interactions related to <italic>oxc</italic> transcription (data not shown). In summary, we found that the type II ODP genes, <italic>frc</italic> and <italic>oxc,</italic> are encoded by multiple gut microbes, but <italic>O. formigenes</italic> dominated this pathway at the transcriptional level. These data provide a baseline for examining disease-associated changes.</p></sec><sec id="s2-5"><title>Validation of ODP detection using ShortBRED</title><p>ShortBRED (<xref ref-type="bibr" rid="bib48">Kaminski et al., 2015</xref>) is a tool for microbiome functional profiling, which clusters protein homologs into clusters, and identifies marker peptide for each cluster, thus potentially achieving high specificity. We reanalyzed all samples using ShortBRED to validate our bioinformatics findings (see Materials and methods). Based on ShortBRED, FRC and OXC were significantly more abundant and more prevalent than OXDD; their abundances were significantly correlated with our previous results (<xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5A</xref>). Consistently, <italic>O. formigenes</italic> was the species with the highest transcriptional activity for FRC (<xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5B</xref>). Specifically, each of the three <italic>O. formigenes</italic> FRC homologs (C3 × 9Y2, C3 × 762, and C3 × 2D4) are distinct from other homologs and from each other; thus, each formed a singleton family (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) with unique peptide markers (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). The three <italic>O. formigenes</italic> FRCs are the most commonly transcribed among FRCs encoded by any taxon. They are present in the metatranscriptome of 50, 52, and 41% of the tested subjects, respectively (<xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5B</xref>, right), and also are among the most abundant (ranks 1, 2, and 5) among all FRC proteins (<xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5B</xref>, right).</p><p>The taxonomic contributions based on BURRITO (<xref ref-type="bibr" rid="bib69">McNally et al., 2018</xref>) (see Materials and methods) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>) are highly concordant with findings using our prior method (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>, metagenome, Healthy). <italic>E. coli</italic> and <italic>O. formigenes</italic> are consistently the two largest contributors, and several Bifidobacterium spp and Lactobacillus spp contributed to a lesser extent.</p><p>ShortBRED did not detect <italic>O. formigenes</italic> OXC in any sample. We reasoned that this under-detection is due to poorly-selected marker peptides. Indeed, for the protein cluster of <italic>O. formigenes</italic> OXC (consists of two <italic>O. formigenes</italic> OXC homologs: C3XBB9 and C3 × 545, with C3 × 545 as the centroid), the makers selected are as follows: (1)short (median length 16.2 amino acids-in comparison, the marker for <italic>O. formigenes</italic> FRC is 300 amino acids) and (2) improperly broken up from long continuous regions (<xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6A</xref>, Marker #1–20). Therefore, we manually generated new markers (Markers #21–24) by combining markers that were one amino acid apart. Using these longer markers, ShortBRED successfully detected OXC using three of the four markers (except for the shortest one) with the expected patterns (<xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6B,C</xref>).</p><p>In summary, all of our major conclusions examined were confirmed with ShortBRED. The diamond-mapping method utilizes reference full length and relies on best alignment scores to assign reads with higher sensitivity, while ShortBRED uses unique regions of reference with higher specificity. Because of their different advantages, the two methods are complementary and both were used for downstream analyses.</p></sec><sec id="s2-6"><title>Increased enteric oxalate levels and reduced microbial ODP expression in IBD patients</title><p>IBD patients, particularly patients suffering from CD, frequently have EH, with oxalate hyperabsorption and calcium oxalate nephrolithiasis (<xref ref-type="bibr" rid="bib20">Corica and Romano, 2016</xref>; <xref ref-type="bibr" rid="bib65">Liu and Nazzal, 2019</xref>; <xref ref-type="bibr" rid="bib68">McConnell et al., 2002</xref>). Ulcerative colitis (UC), regardless of severity and location, is associated with stone formation (<xref ref-type="bibr" rid="bib22">Cury et al., 2013</xref>), but ileocolonic CD is associated with greater nephrolithiasis risk than either ileal or colonic involvement alone (<xref ref-type="bibr" rid="bib22">Cury et al., 2013</xref>). We hypothesized that oxalate degradation by the intestinal microbiome may be impaired in IBD patients, leading to more luminal oxalate in the host available for passive absorption.</p><p>We tested this hypothesis, using the multi-omics data of IBD patients and healthy subjects from the iHMP-IBD study (<xref ref-type="bibr" rid="bib36">Franzosa et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Lloyd-Price et al., 2019</xref>). The patients were stratified by illness: UC (N = 30 subjects) and CD (N = 54), and the CD group was further divided into CD-L3 (N = 25), with ileocolonic phenotype at baseline and CD-nonL3 (N = 29) without, as defined by the L3 IBD Montreal classification (<xref ref-type="bibr" rid="bib86">Satsangi et al., 2006</xref>). Consistent with the clinical nephrolithiasis risk, fecal oxalate relative abundances were elevated in both the UC (p=0.005) and CD (p=0.06) patients compared to healthy controls (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). All of the CD risk was in the CD-L3 patients (p&lt;0.001), and not in the non-CD-L3 patients, indicating that IBD location, particularly ileocolonic involvement, is key for EH risk (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The fecal oxalate levels were not clearly different in relation to disease activity (<xref ref-type="bibr" rid="bib23">Damms and Bischoff, 2008</xref>; <xref ref-type="bibr" rid="bib47">Jowett et al., 2001</xref>; <xref ref-type="bibr" rid="bib67">Manz et al., 2012</xref>; <xref ref-type="bibr" rid="bib79">Pathirana et al., 2018</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). We observed increased fecal oxalate in association with higher inflammation levels (fecal calprotectin &gt; 50 µg/g) (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>); since our number of study subjects was small, this relationship needs to be examined with larger patient cohorts in future studies.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Elevated fecal oxalate and reduced expression of microbiome ODP in IBD patients.</title><p>(<bold>A</bold>). Stool oxalate relative abundance (log<sub>10</sub>) in healthy, UC, CD, CD-L3, or CD-nonL3 subjects from HMP-IBD study. Fecal oxalate relative abundance was determined from untargeted metabolomics data from the iHMP-IBD; measurements related to oxalate were selected and normalized against total metabolites (percent abundance of all observed metabolites) for analysis. L3 refers to the ileocolonic phenotype, according to the Montreal Classification at baseline. Data derived from iHMP-IBD untargeted metabolomics measurements. Prevalence (<bold>B</bold>) and abundance (<bold>C</bold>) of OXDD, FRC, and OXC in metatranscriptomes of healthy, UC, CD, or CD-L3 subjects. The 165 healthy controls are combined from four studies (AMP, US_men, fran, HMP2). *: p&lt;0.05, **: p&lt;0.01, ***: p&lt;0.001, ****: p&lt;0.0001 by multiple-adjusted Mann-Whitney tests in (<bold>A</bold>) and (<bold>C</bold>), by proportion test in (<bold>B</bold>).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Fecal oxalate and ODE expression in healthy and IBD individuals.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63642-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Fecal oxalate log<sub>10</sub> relative abundance in CD patients, according to the Montreal clinical classification (<xref ref-type="bibr" rid="bib86">Satsangi et al., 2006</xref>).</title><p>***p&lt;0.001 by Mann–Whitney test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Comparison of fecal oxalate log<sub>10</sub> relative abundance based on disease activity by fecal calprotectin levels or SCCAI scores.</title><p>(<bold>A</bold>) 148 UC patients were divided into two groups based on SCCAI score above and below 4. (<bold>B</bold>) Subjects were divided based on whether or not fecal calprotection was &gt;50 µg/g (<xref ref-type="bibr" rid="bib23">Damms and Bischoff, 2008</xref>; <xref ref-type="bibr" rid="bib67">Manz et al., 2012</xref>; <xref ref-type="bibr" rid="bib79">Pathirana et al., 2018</xref>). The number of samples in each group is indicated under each box. (<bold>C</bold>) Spearman correlation between fecal calprotectin (µg/g) and fecal oxalate log<sub>10</sub> relative abundance, in samples with calprotectin &gt; 50. (<bold>D</bold>) Fecal calprotectin levels in association with <italic>O. formigenes</italic> status in 152 samples from 38 subjects enrolled in iHMP2, according to clinical diagnosis. The presence of <italic>O. formigenes</italic> was determined by whether <italic>O. formigenes</italic> frc or oxc was detected in the metagenome or metatranscriptome samples collected from the same subject during the same visit (matched accession ID). The number of samples in each group is indicated under each box. Statistics were done using Wilcoxon Rank Sum tests for (<bold>A</bold>), (<bold>B</bold>), and (<bold>D</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Prevalence (<bold>A</bold>) and abundance (<bold>B</bold>) of FRC, and OXC in metatranscriptomes of healthy, UC, CD, or CD-L3 subjects detected by ShortBRED.</title><p>The 165 healthy controls are combined from four studies (AMP, US_men, fran, HMP2). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001 by multiple comparison adjusted proportion tests in (<bold>A</bold>) and Mann–Whitney tests in (<bold>B</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Spearman correlations of fecal oxalate and total transcripts of frc (<bold>A</bold>) or oxc (<bold>B</bold>).</title><p>The x axis is the log<sub>10</sub> abundance of total transcript, which determined by RPKM sum of all homologs in a metatranscriptome samples. The y axis shows the fecal oxalate log<sub>10</sub> relative abundance. Spearman Rho and p values are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>Abundance of <italic>frc</italic> and <italic>oxc</italic> genes in the metagenome of IBD patients and healthy individuals.</title><p>(<bold>A</bold>) Metagenomic prevalence (top) and abundance (bottom) of <italic>frc</italic> and <italic>oxc</italic> in healthy, UC, CD, and CD-L3 subjects. (<bold>B, C</bold>) Spearman correlation of fecal oxalate log<sub>10</sub> relative abundance and total metagenomic <italic>frc</italic> (<bold>B</bold>) and <italic>oxc</italic> (<bold>C</bold>) abundance.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig4-figsupp5-v2.tif"/></fig></fig-group><p>The global transcripts of <italic>frc</italic> and <italic>oxc</italic> were reduced in the IBD patients compared to the controls in all four studies analyzed (<xref ref-type="fig" rid="fig4">Figure 4B,</xref> <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Expression of <italic>oxc</italic> was detected in 57% UC, 54% CD and 48% CD-L3 subjects, lower than the 71% in healthy individuals (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). ODP expression was least impacted in the CD-nonL3 group (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>), in which the fecal oxalate increase was not observed (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The total transcripts of <italic>frc</italic> and <italic>oxc</italic> were also significantly lower in IBD patients (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B</xref>) (p&lt;0.001 for <italic>frc</italic> for all groups compared to healthy, p&lt;0.01 for <italic>oxc</italic> in UC patients compared to healthy). We also observed that <italic>frc</italic> expression was significantly inversely correlated with oxalate relative abundance in the UC group (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A</xref>). The same inverse trend was marginally observed for <italic>oxc</italic> but was not statistically significant (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4B</xref>); thus, this question will need to be examined in larger future cohorts. In contrast to reduced <italic>frc</italic> and <italic>oxc</italic> transcripts in IBD patients, the <italic>frc</italic> and <italic>oxc</italic> genes were significantly more abundant (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>), indicating that the <italic>frc</italic>- and <italic>oxc</italic>-encoding taxa (e.g. Enterobascteriaceae) are enriched in the IBD gut but do not actively express ODP.</p><p>Collectively, these data showing the reduction of ODP-associated transcripts in the IBD patient microbiota suggest their role in the elevated intestinal oxalate levels, and possibly increased susceptibility to nephrolithiasis.</p></sec><sec id="s2-7"><title>Loss of <italic>O. formigenes</italic> and its ODP-associated transcripts in IBD patients</title><p>We next sought to identify the microbial species accounting for the reduced ODP transcripts in the IBD patients. <italic>E. coli</italic> and <italic>O. formigenes</italic> with the largest ODP contributions at the genomic and transcriptional level, respectively, were notable. Using gene and transcript jointly as markers, ODP expression by <italic>O. formigenes</italic> was detected in ~25% of UC and CD patients (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), significantly less than in healthy persons (~70%), either when studies were combined (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) or separate (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). In contrast, <italic>E. coli</italic> ODP was detected in nearly all IBD subjects and was transcribed more frequently compared to healthy subjects (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Consistent with the low overall prevalence, transcripts for <italic>O. formigenes</italic> ODP expression were less abundant (lower RPKM values) in UC, CD, and in CD-L3 patients compared with controls (p&lt;0.01 for all groups) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In the IBD subjects, the observed <italic>O. formigenes</italic> ODP genes were always actively expressed (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Significantly elevated fecal calprotectin levels were observed when <italic>O. formigenes</italic> was absent in healthy individuals and in CD-L3 patients (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Differential ODP expression by human gut microbes in healthy and disease states.</title><p>(<bold>A</bold>) Detection of microbial OXC and FRC in the subject-matched metagenome and metatranscriptome from healthy subjects, UC, CD, or CD-L3 patients. For each species shown, the subjects are divided into one of four categories based on the co-detection of ODE in the matched metagenome and metatranscriptome. (<bold>B</bold>) Expression of microbial FRC and OXC in the metatranscriptomes of healthy subjects, UC, CD, or CD-L3 patients. Boxplot reflects the subjects, in whose metatranscriptome the corresponding enzyme is detected. *p&lt;0.01, **&lt;0.0001 by multiple-adjusted Mann–Whitney tests.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Species contribution to FRC, and OXC in IBD individuals.xlsx.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63642-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig5-v2.tif"/></fig><p>In total, these data indicate that the absence of <italic>O. formigenes</italic> colonization or colonization below the level of detection is responsible for the reduction in global ODP transcripts. <italic>E. coli</italic>, and Lactobacillus and Bifidobacterium spp. use ODPs to defend against oxalate-induced acid stress; their upregulation in IBD appears secondary to the elevated oxalate levels present.</p></sec><sec id="s2-8"><title>Effect on <italic>O. formigenes</italic> colonization on the host urinary and fecal oxalate levels</title><p>To validate our bioinformatics prediction that <italic>O. formigenes</italic> is an important oxalate-degrading organism that can influence oxalate homeostasis in vivo, we examined whether the colonization of <italic>O. formigenes</italic> results in significant reduction in urinary oxalate in mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Mice from our gnotobiotic facility which had a total microbiota 2–3 log<sub>10</sub> lower than conventional mice were fed with diet supplemented with 1% sodium oxalate and 0.5% calcium. The 1% dietary oxalate is lower than previous studies (<xref ref-type="bibr" rid="bib40">Hatch et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Hatch et al., 2011</xref>), in order to reduce chronic kidney damage described previously (<xref ref-type="bibr" rid="bib76">Mulay et al., 2016b</xref>). This diet resulted in significant increase of oxalate (23.3% and 174.8% increase in fecal and urinary oxalate, respectively) compared to normal chow (data not shown). We then colonized these mice with either of two <italic>O. formigenes</italic> strains, including a widely studied lab strain (OXCC13) and a human <italic>O. formigenes</italic> isolate from the stool sample of a patient with primary hyperoxaluria type 1 (PH1) isolated as described (<xref ref-type="bibr" rid="bib4">Allison et al., 1985</xref>). Continued colonization with each was established by qPCR (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Using targeted oxalate assays, the <italic>O. formigenes</italic>-colonized mice had significantly lower urinary and fecal oxalate levels, compared to the non-colonized mice (<xref ref-type="fig" rid="fig6">Figure 6B–C</xref>); the values from the two measurements tended to correlate in individual mice (<xref ref-type="fig" rid="fig6">Figure 6D</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Effect of <italic>O. formigenes</italic> colonization on fecal and urinary oxalate.</title><p>(<bold>A</bold>) Study design of the mouse experiment. C57Bl/6 mice from our gnotobiotic facility were assigned to three groups. At days 0, 2, and 7, mice were gavaged (blue arrowheads) with <italic>O. formigenes</italic> strain OXCC13 (n = 5), <italic>O. formigenes</italic> freshly isolated from a primary hyperoxaluria type 1 (PH1) subject (n = 6), or <italic>O. formigenes</italic> culture medium alone (Media). Mice were fed with normal chow supplemented with 1% sodium oxalate and 0.5% calcium from day −5 until sacrifice. Urine was obtained from a 48 hr collection (one to two mice per pool) prior to sacrifice, and feces were collected at sacrifice (blue arrowhead). (<bold>B, C</bold>) Urinary and fecal oxalate in three mouse groups. Urinary oxalate normalized by creatinine in the 48 hr urine samples and fecal oxalate levels per gram of stool samples in the three experimental groups. *p&lt;0.05, by Tukey’s multiple comparisons test. (<bold>D</bold>) Relationship between fecal and urinary oxalate. Correlation coefficient was computed using Spearman’s r.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Fecal and urinary oxalate in relation to <italic>O. formigenes</italic> colonization in mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63642-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Detection of <italic>Oxalobacter formigenes</italic> by qPCR in the mouse fecal samples before sacrifice.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Detection of <italic>O. formigenes</italic> by qPCR in the intestinal contents (Jej: jejenum, Ile: ileum) and mouse fecal (Fec) samples at sacrifice.</title><p>The dashed line represents the lower limit of detection.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-fig6-figsupp2-v2.tif"/></fig></fig-group><p>In our model, fecal <italic>O. formigenes</italic> averaged ~5×10<sup>6</sup> by qPCR (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). In contrast, <italic>O. formigenes</italic> was below the detection limit (&lt;10<sup>2</sup>) in the jejunum and ileum of most mice (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). These data suggest that <italic>O. formigenes</italic> primarily colonizes and degrades oxalate in the host colon, which is known to be an important site for oxalate absorption.</p><p>Taken together, these findings suggest that <italic>O. formigenes</italic> is sufficient to reduce host urinary and fecal oxalate levels, and support our in silico prediction of the importance of <italic>O. formigenes</italic> to host oxalate homeostasis, with protection against oxalate-induced toxicity.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Oxalate degradation by the human microbiota has been known since the 1940s (<xref ref-type="bibr" rid="bib6">Allison and Cook, 1981</xref>; <xref ref-type="bibr" rid="bib5">Allison et al., 1986</xref>; <xref ref-type="bibr" rid="bib4">Allison et al., 1985</xref>; <xref ref-type="bibr" rid="bib3">Allison et al., 1977</xref>; <xref ref-type="bibr" rid="bib11">Barber and Gallimore, 1940</xref>), but the taxa involved in vivo has not been systematically described. We present the first comprehensive study of human oxalate-degrading microbes and define their individual contributions. We successfully distinguished the taxa that are actively transcribing ODP from those that encode the pathway, but with low expression, by co-analyzing metagenome and metatranscriptome data.</p><p>Our finding that multiple human gut microbes encode ODPs is consistent with prior studies (<xref ref-type="bibr" rid="bib1">Abratt and Reid, 2010</xref>; <xref ref-type="bibr" rid="bib52">Klimesova et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">Mogna et al., 2014</xref>; <xref ref-type="bibr" rid="bib91">Stern et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Ticinesi et al., 2018</xref>). But surprisingly, at the transcriptional level, <italic>O. formigenes</italic> dominates the global ODP, which is consistent with <italic>O. formigenes</italic> being an oxalate autotroph, as well as FRC and OXC being the most abundant proteins during both exponential and lag stages (<xref ref-type="bibr" rid="bib29">Ellis et al., 2016</xref>). These findings were consistent using our method and ShortBRED, which have their unique analytic strengths. The diamond-mapping method utilizes protein full-length information and is completely agnostic. By setting a stringent identity cutoff of 90%, we retain only the high-confidence alignment pairs. The finding generated using this 90% cutoff is consistent with the observations generated through the second method ShortBRED, which uses ODE-specific marker peptides, which provide evidence that the cutoff is highly effective at preventing spurious alignments. By contrast, ShortBRED generated highly specific markers but is limited by several parameter choices (CD-Hit, centroid protein selection, length and identity of short identical regions and final marker). Because of their specific advantages, the two methods are complementary.</p><p>The contrasting genetic and transcriptional ODP differences we observed highlight the importance of analysis beyond the gene level for microbiome studies. There are two critical advantages of an approach that co-analyzes metagenome and metatranscriptome: (1) Detection of genes in the metagenome does not ensure that they are being actively utilized by the indicated taxon. Thus, analyzing metatranscriptomic data allows distinguishing the taxa that are actively contributing to a biological process by generating the relevant proteins. In contrast, for those taxa that are not, the analysis provides a new view of their metabolism, in that although they have the potential for using a certain pathway or metabolite, it is not active under the particular condition tested. (2) Having metatranscriptomic data or other functional readout is particularly useful for cross-comparisons of the microbiome of different cohorts (i.e., diseased versus healthy subjects, in humans or experimental animals). For example, in our study, ODP genes were increased in IBD patients, whereas transcripts were significantly reduced. Specifically, the increased ODP gene abundances were due to the over-representation of <italic>E. coli</italic> strains in IBD patients, which uncommonly transcribe ODP in vivo. In contrast, the decrease of oxalate-degrading gene expression is caused by the loss of <italic>O. formigenes</italic>, which is the dominant microbe that transcribes this pathway. Having observed the differential abundance for a gene does not necessarily indicate functional shifts, as gene abundance is driven by the most abundant taxa, which could be transcriptionally silent. As such, the transcriptional evidence is a better indicator for evaluation of microbiome functional differences. The integrative multi-omics analysis framework built for this study, (now deposited on Github), can be extended to a broad range of microbiome functions.</p><p>EH is frequent in IBD patients, particularly in CD, and in those who underwent Roux-en-Y gastric bypass; the latter population is optimal for study since pre- and post-treatment samples can be easily collected. In the present study, we examine IBD patients, a risk population for EH and nephrolithiasis, and show that the impaired metabolic activity of the microbiota is correlated with enteric oxalate levels, thus nephrolithiasis risk. That fecal oxalate relative abundances were elevated in the iHMP-IBD UC patients, and in the CD patients with ileocolonic involvement, is consistent with their high nephrolithiasis risk (<xref ref-type="bibr" rid="bib22">Cury et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Hylander et al., 1979</xref>; <xref ref-type="bibr" rid="bib44">Hylander et al., 1978</xref>). In this population at risk for EH, the ODP gene abundances are increased, but the extent of gene expression is decreased. This contrast between gene abundance and expression is due to differential ODP transcription in particular microbes.</p><p>IBD patients are known to have low levels of <italic>O. formigenes</italic> colonization (<xref ref-type="bibr" rid="bib56">Kumar et al., 2004</xref>). The oxalate-degrading specialist <italic>O. formigenes</italic> is a gram-negative anaerobe susceptible to multiple antibiotics including macrolides, tetracyclines, metronidazole, and clindamycin (<xref ref-type="bibr" rid="bib51">Kharlamb et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Mittal et al., 2005</xref>). Thus, the reduced colonization of <italic>O. formigenes</italic> in IBD patients might reflect the frequent antibiotic treatments they receive. Human data showed that a single course of antibiotics to eradicate <italic>Helicobacter pylori</italic> results in the long-term suppression of <italic>O. formigenes</italic> colonization (<xref ref-type="bibr" rid="bib51">Kharlamb et al., 2011</xref>). This supports the notion that antibiotics exacerbate microbiome dysbiosis and may lead to secondary conditions such as EH. These findings raise a further potential cost of antibiotic treatment in IBD patients, which should be weighed against potential benefits, especially when infection is not clearly demonstrated. Other changes in the intestinal milieu of IBD patients affecting pH, oxygen, and bile acid levels have been shown to impact <italic>O. formigenes</italic> in vitro (<xref ref-type="bibr" rid="bib26">Duncan et al., 2002</xref>; <xref ref-type="bibr" rid="bib4">Allison et al., 1985</xref>).</p><p>Our findings that <italic>O. formigenes</italic> is the main contributor to oxalate degradation in the healthy state, but is diminished in the IBD population, provides a strong rationale for <italic>O. formigenes-</italic>based restoration therapy. Restoring <italic>O. formigenes</italic> has been tested in primary hyperoxaluria (PH) patients, but yielded mixed results (<xref ref-type="bibr" rid="bib42">Hoppe et al., 2011</xref>; <xref ref-type="bibr" rid="bib43">Hoppe et al., 2017</xref>). However, PH patients might not be the best subjects for restoration because their oxalate toxicity is caused by hepatic overproduction of oxalate, and microbial degradation is restricted to the oxalate secreted into the gut lumen. In EH, the oxalate overload is in the intestinal lumen, which provides a nutrient-rich environment for microbes such as <italic>O. formigenes</italic> to (re)colonize and degrade oxalate prior to absorption into the host circulation. A recent study (<xref ref-type="bibr" rid="bib17">Canales and Hatch, 2017</xref>) of a surgery-induced EH rat model via Roux-en-Y gastric bypass (RYGB), indicated the potential of <italic>O. formigenes</italic> for treating EH in the post-RYGB rat, <italic>O. formigenes</italic> strain OXWR achieved 100% colonization and decreased urinary oxalate by 74% compared to 39% in the sham-operated group. However, levels of <italic>O. formigenes</italic> colonization in EH patients need to be established in future studies. Although PH is a rare disease, EH in IBD patients is common and growing more so, with currently limited treatment options.</p><p>Although our study has significant findings with the potential for translational and mechanistic studies, we acknowledge study limitations. The fact that we only used sequences of proteins instead of the whole genomes during read mapping could lead to false taxa assignments due to possible horizontal gene transfer events. Our analysis was limited to the currently characterized ODPs; therefore, we cannot rule out the existence of other enzymes in the human microbiota to degrade oxalate. Our observations largely rely on metatranscriptomics data, and therefore could be limited by technical biases. It is more difficult to acquire high-quality metatranscriptome, as RNA is less stable and subject to degradation during sample preparation. However, the high consistency across the separate studies (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) done using different sample collection methods, library preparation, and sequencing methods (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>), suggests that our findings are robust with reference to technical variation.</p><p>Also, we did not have access to urinary oxalate or ascertain kidney stone history in our IBD cohort, both critical variables to extend our conclusions. However, previous studies demonstrated intestinal oxalate is predominantly absorbed paracellularly (<xref ref-type="bibr" rid="bib14">Binder, 1974</xref>; <xref ref-type="bibr" rid="bib53">Knauf et al., 2011</xref>; <xref ref-type="bibr" rid="bib87">Saunders et al., 1975</xref>), and oxalate absorption is determined by concentration gradient, gut permeability, and oxalate bioavailability. Thus, colonic oxalate levels should correlate with both renal oxalate and with risk for CaOx stones. In addition to the untargeted metabolomics data used in this study, targeted measurement of fecal and urinary oxalate is desired in future controlled human studies. Oxalate transport in the human intestine has not been completely elucidated, nor has the relative importance of the small and large intestine to oxalate absorption been affirmatively determined. Therefore, colonization site and biogeography may be important factors for oxalate-degrading microbes to reduce host oxalate absorption. The ODP-transcribing microbes identified in the present study are based on fecal samples, which may bias towards organisms colonizing the colon, but not the small intestine. Furthermore, we showed in mice that <italic>O. formigenes</italic> colonization significantly affects oxalate homeostasis in vivo but further colonization with synthetic communities of different oxalate degraders is needed to identify which oxalate-degrading species have the largest impact on oxalate degradation and overall oxalate homeostasis.</p><p>In prior human studies, <italic>O. formigenes</italic> alone can effectively decrease host fecal or urinary oxalate levels, when host are exposed to high oxalate levels (<xref ref-type="bibr" rid="bib17">Canales and Hatch, 2017</xref>; <xref ref-type="bibr" rid="bib46">Jiang et al., 2011</xref>; <xref ref-type="bibr" rid="bib62">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib61">Li et al., 2015</xref>). In our study, <italic>O. formigenes</italic> colonization was below the level of detection in the jejunum and ileum; therefore, it is likely that <italic>O. formigenes</italic> predominately colonizes and performs oxalate degradation in the colon, reducing dietary oxalate being absorbed into the host. A study with germ-free mice (<xref ref-type="bibr" rid="bib62">Li et al., 2016</xref>) observed that colonization of <italic>O. formigenes</italic> strain OXCC13 decreased the mouse fecal oxalate, which is consistent with our findings, but not urinary oxalate. However, several differences were noted between their study and ours, most importantly the use of different mouse strain and their use of a lower oxalate and higher calcium diet (0.1% oxalate and 1% calcium). In our study, both <italic>O. formigenes</italic> strains we tested reduced host urinary and fecal oxalate, although PH1 that was isolated from human showed a greater effect. This difference suggests that establishing the metabolic activity and host adaptability is critical for evaluating the therapeutic potential of individual <italic>O. formigenes</italic> strains.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Meta-omics data of the human microbiome</title><p>Metagenomic and metatranscriptomic data of healthy human subjects were collected from five and four studies, respectively (<xref ref-type="bibr" rid="bib2">Abu-Ali et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Ehrlich, 2011</xref>; <xref ref-type="bibr" rid="bib60">Le Chatelier et al., 2013</xref> <xref ref-type="bibr" rid="bib34">Franzosa et al., 2014</xref>; <xref ref-type="bibr" rid="bib66">Lloyd-Price et al., 2019</xref>; <xref ref-type="bibr" rid="bib82">Petersen et al., 2017</xref>; <xref ref-type="bibr" rid="bib89">Schirmer et al., 2018</xref>). Metagenomic and metatranscriptomic data of healthy humans and IBD subjects were collected from the iHMP-IBD study (<xref ref-type="bibr" rid="bib66">Lloyd-Price et al., 2019</xref>). Each sample was cleaned by KneaData to remove low-quality reads and host-associated reads. The metabolic profiles of each sample were surveyed using HUMAnN2 v0.11.1 (<xref ref-type="bibr" rid="bib35">Franzosa et al., 2018</xref>) under parameters <italic><monospace>--prescreen-threshold</monospace> 0.01</italic>, <italic><monospace>--pathways-database</monospace> <monospace>metacyc_reactions_level4</monospace>, <monospace>metacyc_pathways_structured</monospace></italic><monospace>,</monospace> and <italic><monospace>--protein-database</monospace> uniref50</italic>, for the comparison in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>. Fecal oxalate relative abundance was determined from untargeted metabolomics data from iHMP-IBD; measurements related to oxalate were selected and normalized against total metabolite (percent abundance of all observed metabolites) for analysis.</p></sec><sec id="s4-2"><title>Homologous proteins of ODE</title><p>The protein homolog families of OXDD, FRC, and OXC were characterized by UniProt Interpro (<xref ref-type="bibr" rid="bib71">Mitchell et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">Mulder et al., 2005</xref>) (V70) in protein families IPR017774, IPR017659, and IPR017660, respectively. We acquired the taxonomic origin and amino acid sequences of 2699 OXDD, 1947 FRC, and 1284 OXC homologs. Protein homologs that are 100% identical were then removed, leaving 2519 OXDD, 1556 FRC, and 1037 OXC unique homologs, which were used as a reference database of ODEs for subsequent query against the meta’omics data. Oxalate oxidoreductase (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), a recently discovered enzyme for which there only is limited information (<xref ref-type="bibr" rid="bib7">Anand et al., 2002</xref>; <xref ref-type="bibr" rid="bib25">Dumas et al., 1993</xref>; <xref ref-type="bibr" rid="bib38">Grąz et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Kumar et al., 2011</xref>; <xref ref-type="bibr" rid="bib92">Svedruzić et al., 2007</xref>; <xref ref-type="bibr" rid="bib93">Tanner et al., 2001</xref>), was not considered in this present study.</p></sec><sec id="s4-3"><title>Pairwise identity between ODE protein homologs</title><p>Multiple sequence alignments were performed among the unique protein homologs separately, by muscle (<xref ref-type="bibr" rid="bib27">Edgar, 2004</xref>) in seaview v4.7 (<xref ref-type="bibr" rid="bib37">Gouy et al., 2010</xref>), and alignments were trimmed and imported into R. The pairwise alignment distance <inline-formula><mml:math id="inf1"><mml:mi>d</mml:mi></mml:math></inline-formula> was calculated using function <italic>dist.alignment</italic> in the seqinR package (<xref ref-type="bibr" rid="bib18">Charif et al., 2005</xref>) based on identity or Fitch matrix (<xref ref-type="bibr" rid="bib31">Fitch, 1966</xref>). The alignment distance <inline-formula><mml:math id="inf2"><mml:mi>d</mml:mi></mml:math></inline-formula> was subsequently converted to percent protein identity <inline-formula><mml:math id="inf3"><mml:mrow><mml:mn>100</mml:mn><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, following the documentation of <italic>dist.alignment</italic>.</p></sec><sec id="s4-4"><title>Detection of ODE in the meta-omics data</title><p>We used two different approaches with complementary methodologies to ensure the conclusions are robust.</p><list list-type="order"><list-item><p>The first method we used is an agnostic approach that uses full protein sequences with high sensitivity. The quality-filtered meta’omics data were aligned against the reference protein databases consisting of the unique ODE homologs, by diamond blastx (<xref ref-type="bibr" rid="bib16">Buchfink et al., 2015</xref>), with best hit returned (--max-target-seqs 1). Alignments with identity &lt;90% were arbitrarily filtered out to prevent non-ODE reads from aligning to the ODE-specific reference proteins due to local similarity (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>) By setting a stringent identity cutoff of 90%, we retain only the high-confidence alignment pairs. The abundance of each ODE protein homolog was calculated as reads per kilobase per million (RPKM) in each sample. When multiple timepoints were available, each subject was represented by the mean measurements across all samples provided.</p></list-item><list-item><p>We also used ShortBRED, which compares ODEs with all other known proteins to identify highly specific marker peptides, and thus can achieve high specificity. Using <italic>ShortBRED-identify</italic>, FRC, OXC, and OXDD were clustered into 202, 190, and 846 families respectively, with a centroid/representative protein selected for each family (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Then those centroids were compared against the uniref90 reference protein database (the ODE homologs were excluded), to remove the common region for identification of short peptide markers (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Lastly, filtered meta-omics reads were mapped against those peptide markers using <italic>ShortBRED-quantify</italic> with parameters <italic><monospace>--pctlength</monospace> 0.5</italic> and <italic><monospace>--id</monospace> 0.9</italic>, to calculate the RPKM for each protein family. Default parameters were used unless noted otherwise.</p></list-item></list></sec><sec id="s4-5"><title>Population-level contribution to ODE</title><p>The population-level contribution of a species to ODE was designed as a measurement to take both prevalence and abundance information into consideration. It is calculated for each ODE separately, based on their abundances (RPKM values). Using oxc as the example, suppose there are <inline-formula><mml:math id="inf4"><mml:mi>M</mml:mi></mml:math></inline-formula><italic>oxc</italic>-coding species and <inline-formula><mml:math id="inf5"><mml:mi>N</mml:mi></mml:math></inline-formula> samples. In any given sample <inline-formula><mml:math id="inf6"><mml:mi>j</mml:mi></mml:math></inline-formula>, the contribution of species <inline-formula><mml:math id="inf7"><mml:mi>i</mml:mi></mml:math></inline-formula> to OXC, <inline-formula><mml:math id="inf8"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, is represented by its relative oxc abundance, calculated from<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:munderover><mml:mstyle displaystyle="true" mathsize="140%"><mml:mo movablelimits="false">∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo> </mml:mo></mml:mrow></mml:math></disp-formula>where the <inline-formula><mml:math id="inf9"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denotes the RPKM<sub>oxc</sub> of species <inline-formula><mml:math id="inf10"><mml:mi>i</mml:mi></mml:math></inline-formula> in sample <inline-formula><mml:math id="inf11"><mml:mi>j</mml:mi></mml:math></inline-formula>. In this way, we normalize across samples with the total contribution in any OXC-positive samples fixed to 1, and to 0 in any OXC-negative samples.</p><p>The population-level contribution of species <inline-formula><mml:math id="inf12"><mml:mi>i</mml:mi></mml:math></inline-formula>: <inline-formula><mml:math id="inf13"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, can be subsequently calculated from summating contribution of species <inline-formula><mml:math id="inf14"><mml:mi>i</mml:mi></mml:math></inline-formula> in <inline-formula><mml:math id="inf15"><mml:mi>N</mml:mi></mml:math></inline-formula> samples, as follows<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo> </mml:mo><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:munderover><mml:mstyle displaystyle="true" mathsize="140%"><mml:mo movablelimits="false">∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo> </mml:mo></mml:mrow></mml:math></disp-formula></p><p>Note that population-level contribution of species monotonically increases with sample size <inline-formula><mml:math id="inf16"><mml:mi>N</mml:mi></mml:math></inline-formula>. Therefore, it has been transformed to relative scale when being compared across different populations or different sample types (metagenome vs. metatranscriptome), such as in <xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref> and 12.</p></sec><sec id="s4-6"><title>BURRITO for linking function to taxa</title><p>BURRITO (<xref ref-type="bibr" rid="bib69">McNally et al., 2018</xref>) was used to deconvolve ODE genes into taxa at the species level. Taxonomic profiles of healthy metagenome (n = 2539 samples) were generated by Metaphlan2 (<xref ref-type="bibr" rid="bib95">Truong et al., 2015</xref>) under default parameters. In each sample, RPKM of all FRC or OXC homologs were summed as total abundance of <italic>frc</italic> or <italic>oxc</italic> genes and then supplied to BURRITO. The genomic content file was derived from taxonomic annotation of protein homologs from UniProt Interpro. We assumed one copy of <italic>frc</italic> and <italic>oxc</italic> for each genome to minimize bias, as such information is not available for all species.</p></sec><sec id="s4-7"><title>Network analysis</title><p>A network analysis of <italic>oxc</italic> or <italic>frc</italic> expression from microbial species used SpiecEasi (<xref ref-type="bibr" rid="bib58">Kurtz et al., 2015</xref>). The raw RPKM values were used, and networks were constructed under default parameters <italic>method='mb'</italic>, <italic>sel.criterion='bstars'</italic>, <italic>lambda.min.ratio = 2e-2</italic>, <italic>nlambda = 100</italic>, and <italic>pulsar.params=list(rep.num = 20, ncores = 2)</italic>.</p></sec><sec id="s4-8"><title>Code availability</title><p>Source code of the pipeline can be found on Github via <ext-link ext-link-type="uri" xlink:href="https://github.com/ml3958/FindTaxaCtrbt">https://github.com/ml3958/FindTaxaCtrbt</ext-link> (<xref ref-type="bibr" rid="bib64">Liu, 2021</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:b4d7dc8974adaca3e6ed9b9e7b1c8f8adf2e1741;origin=https://github.com/ml3958/FindTaxaCtrbt;visit=swh:1:snp:8f7fffcb012c57648cdb8a6b798abf40ec4d8050;anchor=swh:1:rev:13bbc4662f458bff327e348162bf51d875ed34d3/">swh:1:rev:13bbc4662f458bff327e348162bf51d875ed34d3</ext-link>). Downstream analysis scripts are available per request.</p></sec><sec id="s4-9"><title><italic>O. formigenes</italic> isolation and culturing</title><p> <italic>O. formigenes</italic> strain PH1 was isolated from the stool sample of a primary hyperoxaluria patient using methods described in <xref ref-type="bibr" rid="bib4">Allison et al., 1985</xref>. Both strains were cultured in defined oxalate broth as described (<xref ref-type="bibr" rid="bib4">Allison et al., 1985</xref>), except that the concentration of oxalate is 50 mM. <italic>O. formigenes</italic> was cultured at 37°C in an anaerobic chamber before each mouse gavage.</p></sec><sec id="s4-10"><title><italic>O. formigenes</italic> colonization of mice</title><p>A total of 17 C57Bl/6 male mice maintained in our gnotobiotic facility were used. The median of mouse baseline microbiome 16S qPCR measurements was 2.6 × 10<sup>5</sup>, which is significantly lower than that of SPF mice (usually 10<sup>8</sup> or 10<sup>9</sup> in our experiments, representing &lt;0.1% of the absolute abundance). The taxa detected in the baseline samples (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>) did not lead to colonization resistance to the introduced <italic>O. formigenes</italic> strains.</p><p>At days 0, 2, and 7, mice were gavaged with 100 µl from a 24 hr growing culture of <italic>O. formigenes</italic> strain OXCC13 (n = 5), <italic>O. formigenes</italic> freshly isolated from a PH1 subject (n = 6), and <italic>O. formigenes</italic> culture medium alone (n = 6). Mice were fed normal chow supplemented with 1% sodium oxalate from study commencement (day −5) until mouse sacrifice at day 35. We did not perform an explicit power analysis since there is no previous data on our animal model and experimental conditions. We thought that five to six mice per group is a reasonable number of mice per group to show a significant change in urinary oxalate. Biological replicates are parallel measurements of biologically distinct samples that capture random biological variation, which may itself be a subject of study or a noise source. In each mouse group, we performed five to six biological replicates by gavaging material (culture media, growing culture of strain OXCC13 or PH1) into five to six mice.</p></sec><sec id="s4-11"><title>DNA extraction and <italic>O. formigenes</italic> quantitative PCR</title><p>Murine fecal pellets or intestinal contents were collected and stored at −80°C until DNA was extracted, using the MoBio 96-well extraction kit, following the manufacturer’s instructions. We confirmed that mice were colonized with <italic>O. formigenes</italic> at sacrifice using qPCR of fecal samples (Figure S16). qPCR was used to quantitate the number of copies of the oxc mRNA using the LightCycler 480 SYBR Green I Master Mix and run using the LightCycler 480 system. Paired primers (forward 5′-TGT-TTG-TCG-GCA-TTC-CTA-TC-3′, reverse 5′-TTG-GGA-AGC-AGT-TGG-TGG-3′) were used under the conditions: 95°C for 10 min, followed by 40 cycles of: 95°C for 23 s, 63°C for 20 s, 70°C for 40 s, and a final 30 s at 40°C as described (<xref ref-type="bibr" rid="bib81">Pebenito et al., 2019</xref>).</p></sec><sec id="s4-12"><title>Fecal and urinary collections and oxalate measurements</title><p>Mice were housed (n = 1 or 2) in metabolic cages, and 48 hr collections (1–2 mice per urine pool) were made under mineral oil into vessels containing crystal thymol as a preservative. Urinary oxalate (mg/dl) and creatinine (mg/dl) concentrations were determined in acidified (HCl) samples collected from all mice over a 48 hr period by Litholink Corp (Chicago, IL). Fecal pellets were collected at the end of the urine collections. Fecal pellets were acidified using 2M HCl, vortexed for 20 min, and then centrifuged at 21,000 g at room temperature, and supernatant fecal water collected using described methods (<xref ref-type="bibr" rid="bib46">Jiang et al., 2011</xref>). Fecal water oxalate was measured using an oxalate calorimetric assay (Abcam, ab196990, Cambridge, UK) per the manufacturer’s instructions. Technical replicates are repeated measurements of the same sample that represent independent measures of the random noise associated with protocols or equipment. Fecal oxalate and qPCR were measured in duplicates.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. David Goldfarb and Xuhui Zheng for their helpful comments. We thank Dr. Tim Borbet for the helpful discussion and input. Funding: This study was supported in part by U01AI22285, R01DK110014, and the Rare Kidney Stone Consortium (U54 DK083908) from the National Institutes of Health, by the C and D and Zlinkoff Funds, Oxalosis and Hyperoxaluria Foundation-American Society of Nephrology career development grant, and the TransAtlantic Partnership of the Fondation LeDucq.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an employee of Litholink</p></fn><fn fn-type="COI-statement" id="conf3"><p>is an employee of Genentech</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation</p></fn><fn fn-type="con" id="con3"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="conf5"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#IA16-00822) of the New York University Langone Medical Center.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Tables.</title><p>(<bold>a</bold>) Description of populations used in the present study. (<bold>b</bold>) Population-level contribution of species to metagenomic or metatranscriptomic OXC, in healthy, ulcerative colitis (UC), or Crohn’s disease (CD) patients. (<bold>c</bold>) Population-level contribution of species to metagenomic or metatranscriptomic FRC, in healthy, UC, or CD patients. (<bold>d</bold>) Taxonomic contributions to <italic>frc</italic> or <italic>oxc</italic> genes* inferred by BURRITO in 2359 metagenomic samples (see Materials and methods for detailed description). (<bold>e</bold>) The dominant taxa detected by 16S rRNA sequencing in the baseline fecal samples (n = 17) from the mouse study in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-63642-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Proteins associated with each protein cluster based on ShortBRED.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63642-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Marker pepetide picked for each protein cluster based on ShortBRED.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-63642-supp3-v2.zip"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-63642-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2–5.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>LM</given-names></name><name><surname>Bautista</surname><given-names>EJ</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Hanson</surname><given-names>BM</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Lek</surname><given-names>SH</given-names></name><name><surname>Sodergren</surname><given-names>E</given-names></name><name><surname>Weinstock</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Athlete Microbiome Project (AMP)</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA305507">PRJNA305507</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Eric</surname><given-names>FA</given-names></name><name><surname>Morgan</surname><given-names>XC</given-names></name><name><surname>Segata</surname><given-names>N</given-names></name><name><surname>Waldron</surname><given-names>L</given-names></name><name><surname>Reyes</surname><given-names>J</given-names></name><name><surname>Earl</surname><given-names>AM</given-names></name><name><surname>Giannoukos</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><data-title>fran</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA188481">PRJNA188481</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Lloyd-Price</surname><given-names>J</given-names></name><name><surname>Arze</surname><given-names>C</given-names></name><name><surname>Ananthakrishnan</surname><given-names>AN</given-names></name><name><surname>Schirmer</surname><given-names>M</given-names></name><name><surname>Avila-Pacheco</surname><given-names>J</given-names></name><name><surname>Poon</surname><given-names>TW</given-names></name><name><surname>Andrews</surname><given-names>E</given-names></name><name><surname>Ajami</surname><given-names>NJ</given-names></name><name><surname>Bonham</surname><given-names>KS</given-names></name><name><surname>Brislawn</surname><given-names>CJ</given-names></name><name><surname>Casero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>iHMP</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111889">GSE111889</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RS</given-names></name><name><surname>Abu-Ali</surname><given-names>GS</given-names></name><name><surname>Drew</surname><given-names>DA</given-names></name><name><surname>Lloyd-Price</surname><given-names>J</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Lochhead</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Ivey</surname><given-names>KL</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>GT</given-names></name><name><surname>DuLong</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Mallick</surname><given-names>H</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Izard</surname><given-names>J</given-names></name><name><surname>Huttenhower</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>US men</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/354235">PRJNA354235</pub-id></element-citation></p><p><element-citation id="dataset7" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Le Chatelier</surname><given-names>E</given-names></name><name><surname>Nielsen</surname><given-names>T</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Prifti</surname><given-names>E</given-names></name><name><surname>Hildebrand</surname><given-names>F</given-names></name><name><surname>Falony</surname><given-names>G</given-names></name><name><surname>Almeida</surname><given-names>M</given-names></name><name><surname>Arumugam</surname><given-names>M</given-names></name><name><surname>Batto</surname><given-names>JM</given-names></name><name><surname>Kennedy</surname><given-names>S</given-names></name><name><surname>Leonard</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Burgdorf</surname><given-names>K</given-names></name><name><surname>Grarup</surname><given-names>N</given-names></name><name><surname>Jørgensen</surname><given-names>T</given-names></name><name><surname>Brandslund</surname><given-names>I</given-names></name><name><surname>Nielsen</surname><given-names>HB</given-names></name><name><surname>Juncker</surname><given-names>AS</given-names></name><name><surname>Bertalan</surname><given-names>M</given-names></name><name><surname>Levenez</surname><given-names>F</given-names></name><name><surname>Pons</surname><given-names>N</given-names></name><name><surname>Rasmussen</surname><given-names>S</given-names></name><name><surname>Sunagawa</surname><given-names>S</given-names></name><name><surname>Tap</surname><given-names>J</given-names></name><name><surname>Tims</surname><given-names>S</given-names></name><name><surname>Zoetendal</surname><given-names>EG</given-names></name><name><surname>Brunak</surname><given-names>S</given-names></name><name><surname>Clément</surname><given-names>K</given-names></name><name><surname>Doré</surname><given-names>J</given-names></name><name><surname>Kleerebezem</surname><given-names>M</given-names></name><name><surname>Kristiansen</surname><given-names>K</given-names></name><name><surname>Renault</surname><given-names>P</given-names></name><name><surname>Sicheritz-Ponten</surname><given-names>T</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name><name><surname>Zucker</surname><given-names>JD</given-names></name><name><surname>Raes</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><collab>MetaHIT consortium</collab><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ehrlich</surname><given-names>SD</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>MetaHIT</data-title><source>EBI European Nucleotide Archive</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB4336">PRJEB4336</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abratt</surname> <given-names>VR</given-names></name><name><surname>Reid</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Oxalate-degrading Bacteria of the human gut as probiotics in the management of kidney stone disease</article-title><source>Advances in Applied Microbiology</source><volume>72</volume><fpage>63</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/S0065-2164(10)72003-7</pub-id><pub-id pub-id-type="pmid">20602988</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Ali</surname> <given-names>GS</given-names></name><name><surname>Mehta</surname> <given-names>RS</given-names></name><name><surname>Lloyd-Price</surname> <given-names>J</given-names></name><name><surname>Mallick</surname> <given-names>H</given-names></name><name><surname>Branck</surname> <given-names>T</given-names></name><name><surname>Ivey</surname> <given-names>KL</given-names></name><name><surname>Drew</surname> <given-names>DA</given-names></name><name><surname>DuLong</surname> <given-names>C</given-names></name><name><surname>Rimm</surname> <given-names>E</given-names></name><name><surname>Izard</surname> <given-names>J</given-names></name><name><surname>Chan</surname> <given-names>AT</given-names></name><name><surname>Huttenhower</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metatranscriptome of human faecal microbial communities in a cohort of adult men</article-title><source>Nature Microbiology</source><volume>3</volume><fpage>356</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/s41564-017-0084-4</pub-id><pub-id pub-id-type="pmid">29335555</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname> <given-names>MJ</given-names></name><name><surname>Littledike</surname> <given-names>ET</given-names></name><name><surname>James</surname> <given-names>LF</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Changes in ruminal oxalate degradation rates associated with adaptation to oxalate ingestion</article-title><source>Journal of Animal Science</source><volume>45</volume><fpage>1173</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.2527/jas1977.4551173x</pub-id><pub-id pub-id-type="pmid">599103</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname> <given-names>MJ</given-names></name><name><surname>Dawson</surname> <given-names>KA</given-names></name><name><surname>Mayberry</surname> <given-names>WR</given-names></name><name><surname>Foss</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract</article-title><source>Archives of Microbiology</source><volume>141</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/BF00446731</pub-id><pub-id pub-id-type="pmid">3994481</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname> <given-names>MJ</given-names></name><name><surname>Cook</surname> <given-names>HM</given-names></name><name><surname>Milne</surname> <given-names>DB</given-names></name><name><surname>Gallagher</surname> <given-names>S</given-names></name><name><surname>Clayman</surname> <given-names>RV</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Oxalate degradation by gastrointestinal Bacteria from humans</article-title><source>The Journal of Nutrition</source><volume>116</volume><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1093/jn/116.3.455</pub-id><pub-id pub-id-type="pmid">3950772</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname> <given-names>MJ</given-names></name><name><surname>Cook</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Oxalate degradation by microbes of the large bowel of herbivores: the effect of dietary oxalate</article-title><source>Science</source><volume>212</volume><fpage>675</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1126/science.7221555</pub-id><pub-id pub-id-type="pmid">7221555</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname> <given-names>R</given-names></name><name><surname>Dorrestein</surname> <given-names>PC</given-names></name><name><surname>Kinsland</surname> <given-names>C</given-names></name><name><surname>Begley</surname> <given-names>TP</given-names></name><name><surname>Ealick</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Structure of oxalate decarboxylase from <italic>Bacillus subtilis</italic> at 1.75 A resolution</article-title><source>Biochemistry</source><volume>41</volume><fpage>7659</fpage><lpage>7669</lpage><pub-id pub-id-type="doi">10.1021/bi0200965</pub-id><pub-id pub-id-type="pmid">12056897</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvans</surname> <given-names>D</given-names></name><name><surname>Jung</surname> <given-names>YC</given-names></name><name><surname>Antonopoulos</surname> <given-names>D</given-names></name><name><surname>Koval</surname> <given-names>J</given-names></name><name><surname>Granja</surname> <given-names>I</given-names></name><name><surname>Bashir</surname> <given-names>M</given-names></name><name><surname>Karrar</surname> <given-names>E</given-names></name><name><surname>Roy-Chowdhury</surname> <given-names>J</given-names></name><name><surname>Musch</surname> <given-names>M</given-names></name><name><surname>Asplin</surname> <given-names>J</given-names></name><name><surname>Chang</surname> <given-names>E</given-names></name><name><surname>Hassan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Oxalobacter formigenes-</italic>Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells</article-title><source>Journal of the American Society of Nephrology</source><volume>28</volume><fpage>876</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1681/ASN.2016020132</pub-id><pub-id pub-id-type="pmid">27738124</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asplin</surname> <given-names>J</given-names></name><name><surname>Parks</surname> <given-names>J</given-names></name><name><surname>Lingeman</surname> <given-names>J</given-names></name><name><surname>Kahnoski</surname> <given-names>R</given-names></name><name><surname>Mardis</surname> <given-names>H</given-names></name><name><surname>Lacey</surname> <given-names>S</given-names></name><name><surname>Goldfarb</surname> <given-names>D</given-names></name><name><surname>Grasso</surname> <given-names>M</given-names></name><name><surname>Coe</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Supersaturation and stone composition in a network of dispersed treatment sites</article-title><source>Journal of Urology</source><volume>159</volume><fpage>1821</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(01)63164-1</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azcarate-Peril</surname> <given-names>MA</given-names></name><name><surname>Bruno-Bárcena</surname> <given-names>JM</given-names></name><name><surname>Hassan</surname> <given-names>HM</given-names></name><name><surname>Klaenhammer</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from Lactobacillus acidophilus</article-title><source>Applied and Environmental Microbiology</source><volume>72</volume><fpage>1891</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1128/AEM.72.3.1891-1899.2006</pub-id><pub-id pub-id-type="pmid">16517636</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname> <given-names>HH</given-names></name><name><surname>Gallimore</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="1940">1940</year><article-title>The metabolism of oxalic acid in the animal body</article-title><source>Biochemical Journal</source><volume>34</volume><fpage>144</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1042/bj0340144</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname> <given-names>C</given-names></name><name><surname>Nazzal</surname> <given-names>L</given-names></name><name><surname>Goldfarb</surname> <given-names>DS</given-names></name><name><surname>Blaser</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The presence of Oxalobacter formigenes in the microbiome of healthy young adults</article-title><source>The Journal of Urology</source><volume>195</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2015.08.070</pub-id><pub-id pub-id-type="pmid">26292041</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname> <given-names>BB</given-names></name><name><surname>Hoyer-Kuhn</surname> <given-names>H</given-names></name><name><surname>Göbel</surname> <given-names>H</given-names></name><name><surname>Habbig</surname> <given-names>S</given-names></name><name><surname>Hoppe</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions</article-title><source>Expert Opinion on Investigational Drugs</source><volume>22</volume><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1517/13543784.2013.741587</pub-id><pub-id pub-id-type="pmid">23167815</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binder</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="1974">1974</year><article-title>Intestinal oxalate absorption</article-title><source>Gastroenterology</source><volume>67</volume><fpage>441</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(19)32846-X</pub-id><pub-id pub-id-type="pmid">4852527</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackmore</surname> <given-names>MA</given-names></name><name><surname>Quayle</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="1970">1970</year><article-title>Microbial growth on oxalate by a route not involving glyoxylate carboligase</article-title><source>Biochemical Journal</source><volume>118</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1042/bj1180053</pub-id><pub-id pub-id-type="pmid">5472155</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchfink</surname> <given-names>B</given-names></name><name><surname>Xie</surname> <given-names>C</given-names></name><name><surname>Huson</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fast and sensitive protein alignment using DIAMOND</article-title><source>Nature Methods</source><volume>12</volume><fpage>59</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3176</pub-id><pub-id pub-id-type="pmid">25402007</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canales</surname> <given-names>BK</given-names></name><name><surname>Hatch</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria</article-title><source>Surgery for Obesity and Related Diseases</source><volume>13</volume><fpage>1152</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1016/j.soard.2017.03.014</pub-id><pub-id pub-id-type="pmid">28552742</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charif</surname> <given-names>D</given-names></name><name><surname>Thioulouse</surname> <given-names>J</given-names></name><name><surname>Lobry</surname> <given-names>JR</given-names></name><name><surname>Perrière</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Online synonymous Codon usage analyses with the ade4 and seqinR packages</article-title><source>Bioinformatics</source><volume>21</volume><fpage>545</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti037</pub-id><pub-id pub-id-type="pmid">15374859</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname> <given-names>JG</given-names></name><name><surname>Gebhart</surname> <given-names>CJ</given-names></name><name><surname>Furrow</surname> <given-names>E</given-names></name><name><surname>Lulich</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Assessment of in vitro oxalate degradation by Lactobacillus species cultured from veterinary probiotics</article-title><source>American Journal of Veterinary Research</source><volume>76</volume><fpage>801</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.2460/ajvr.76.9.801</pub-id><pub-id pub-id-type="pmid">26309108</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corica</surname> <given-names>D</given-names></name><name><surname>Romano</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Renal involvement in inflammatory bowel diseases</article-title><source>Journal of Crohn's and Colitis</source><volume>10</volume><fpage>226</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjv138</pub-id><pub-id pub-id-type="pmid">26223844</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornick</surname> <given-names>NA</given-names></name><name><surname>Allison</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Assimilation of oxalate, acetate, and CO2 by Oxalobacter formigenes</article-title><source>Canadian Journal of Microbiology</source><volume>42</volume><fpage>1081</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1139/m96-138</pub-id><pub-id pub-id-type="pmid">8941983</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cury</surname> <given-names>DB</given-names></name><name><surname>Moss</surname> <given-names>AC</given-names></name><name><surname>Schor</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nephrolithiasis in patients with inflammatory bowel disease in the community</article-title><source>International Journal of Nephrology and Renovascular Disease</source><volume>6</volume><fpage>139</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.2147/IJNRD.S45466</pub-id><pub-id pub-id-type="pmid">23935383</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damms</surname> <given-names>A</given-names></name><name><surname>Bischoff</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases</article-title><source>International Journal of Colorectal Disease</source><volume>23</volume><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1007/s00384-008-0506-0</pub-id><pub-id pub-id-type="pmid">18629518</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniel</surname> <given-names>SL</given-names></name><name><surname>Pilsl</surname> <given-names>C</given-names></name><name><surname>Drake</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Oxalate metabolism by the acetogenic bacterium Moorella thermoacetica</article-title><source>FEMS Microbiology Letters</source><volume>231</volume><fpage>39</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/S0378-1097(03)00924-8</pub-id><pub-id pub-id-type="pmid">14769464</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname> <given-names>B</given-names></name><name><surname>Sailland</surname> <given-names>A</given-names></name><name><surname>Cheviet</surname> <given-names>JP</given-names></name><name><surname>Freyssinet</surname> <given-names>G</given-names></name><name><surname>Pallett</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Identification of barley oxalate oxidase as a germin-like protein</article-title><source>Comptes Rendus De l'Academie Des Sciences. Serie III, Sciences De La Vie</source><volume>316</volume><fpage>793</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">8044704</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname> <given-names>SH</given-names></name><name><surname>Richardson</surname> <given-names>AJ</given-names></name><name><surname>Kaul</surname> <given-names>P</given-names></name><name><surname>Holmes</surname> <given-names>RP</given-names></name><name><surname>Allison</surname> <given-names>MJ</given-names></name><name><surname>Stewart</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Oxalobacter formigenes and its potential role in human health</article-title><source>Applied and Environmental Microbiology</source><volume>68</volume><fpage>3841</fpage><lpage>3847</lpage><pub-id pub-id-type="doi">10.1128/AEM.68.8.3841-3847.2002</pub-id><pub-id pub-id-type="pmid">12147479</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgar</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>MUSCLE: a multiple sequence alignment method with reduced time and space complexity</article-title><source>BMC Bioinformatics</source><volume>5</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-5-113</pub-id><pub-id pub-id-type="pmid">15318951</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ehrlich</surname> <given-names>SD</given-names></name></person-group><year iso-8601-date="2011">2011</year><chapter-title>MetaHIT: The European Union Project on Metagenomics of the Human Intestinal Tract</chapter-title><person-group person-group-type="editor"><name><surname>Nelson</surname> <given-names>K</given-names></name></person-group><source>Metagenomics of the Human Body</source><publisher-name>Springer</publisher-name><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1007/978-1-4419-7089-3_15</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname> <given-names>ME</given-names></name><name><surname>Mobley</surname> <given-names>JA</given-names></name><name><surname>Holmes</surname> <given-names>RP</given-names></name><name><surname>Knight</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Proteome dynamics of the specialist oxalate degrader Oxalobacter formigenes</article-title><source>Journal of Proteomics &amp; Bioinformatics</source><volume>9</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.4172/jpb.1000384</pub-id><pub-id pub-id-type="pmid">26924912</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Federici</surname> <given-names>F</given-names></name><name><surname>Vitali</surname> <given-names>B</given-names></name><name><surname>Gotti</surname> <given-names>R</given-names></name><name><surname>Pasca</surname> <given-names>MR</given-names></name><name><surname>Gobbi</surname> <given-names>S</given-names></name><name><surname>Peck</surname> <given-names>AB</given-names></name><name><surname>Brigidi</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Characterization and heterologous expression of the oxalyl coenzyme A decarboxylase gene from Bifidobacterium lactis</article-title><source>Applied and Environmental Microbiology</source><volume>70</volume><fpage>5066</fpage><lpage>5073</lpage><pub-id pub-id-type="doi">10.1128/AEM.70.9.5066-5073.2004</pub-id><pub-id pub-id-type="pmid">15345383</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitch</surname> <given-names>WM</given-names></name></person-group><year iso-8601-date="1966">1966</year><article-title>An improved method of testing for evolutionary homology</article-title><source>Journal of Molecular Biology</source><volume>16</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(66)80258-9</pub-id><pub-id pub-id-type="pmid">5917736</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontenot</surname> <given-names>EM</given-names></name><name><surname>Ezelle</surname> <given-names>KE</given-names></name><name><surname>Gabreski</surname> <given-names>LN</given-names></name><name><surname>Giglio</surname> <given-names>ER</given-names></name><name><surname>McAfee</surname> <given-names>JM</given-names></name><name><surname>Mills</surname> <given-names>AC</given-names></name><name><surname>Qureshi</surname> <given-names>MN</given-names></name><name><surname>Salmon</surname> <given-names>KM</given-names></name><name><surname>Toyota</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>YfdW and YfdU are required for oxalate-induced acid tolerance in <italic>Escherichia coli</italic> K-12</article-title><source>Journal of Bacteriology</source><volume>195</volume><fpage>1446</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1128/JB.01936-12</pub-id><pub-id pub-id-type="pmid">23335415</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>HU</given-names></name><name><surname>Nakata</surname> <given-names>PA</given-names></name><name><surname>Browse</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A previously unknown oxalyl-CoA synthetase is important for oxalate catabolism in Arabidopsis</article-title><source>The Plant Cell</source><volume>24</volume><fpage>1217</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1105/tpc.112.096032</pub-id><pub-id pub-id-type="pmid">22447686</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzosa</surname> <given-names>EA</given-names></name><name><surname>Morgan</surname> <given-names>XC</given-names></name><name><surname>Segata</surname> <given-names>N</given-names></name><name><surname>Waldron</surname> <given-names>L</given-names></name><name><surname>Reyes</surname> <given-names>J</given-names></name><name><surname>Earl</surname> <given-names>AM</given-names></name><name><surname>Giannoukos</surname> <given-names>G</given-names></name><name><surname>Boylan</surname> <given-names>MR</given-names></name><name><surname>Ciulla</surname> <given-names>D</given-names></name><name><surname>Gevers</surname> <given-names>D</given-names></name><name><surname>Izard</surname> <given-names>J</given-names></name><name><surname>Garrett</surname> <given-names>WS</given-names></name><name><surname>Chan</surname> <given-names>AT</given-names></name><name><surname>Huttenhower</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Relating the metatranscriptome and metagenome of the human gut</article-title><source>PNAS</source><volume>111</volume><fpage>E2329</fpage><lpage>E2338</lpage><pub-id pub-id-type="doi">10.1073/pnas.1319284111</pub-id><pub-id pub-id-type="pmid">24843156</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzosa</surname> <given-names>EA</given-names></name><name><surname>McIver</surname> <given-names>LJ</given-names></name><name><surname>Rahnavard</surname> <given-names>G</given-names></name><name><surname>Thompson</surname> <given-names>LR</given-names></name><name><surname>Schirmer</surname> <given-names>M</given-names></name><name><surname>Weingart</surname> <given-names>G</given-names></name><name><surname>Lipson</surname> <given-names>KS</given-names></name><name><surname>Knight</surname> <given-names>R</given-names></name><name><surname>Caporaso</surname> <given-names>JG</given-names></name><name><surname>Segata</surname> <given-names>N</given-names></name><name><surname>Huttenhower</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Species-level functional profiling of metagenomes and metatranscriptomes</article-title><source>Nature Methods</source><volume>15</volume><fpage>962</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1038/s41592-018-0176-y</pub-id><pub-id pub-id-type="pmid">30377376</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzosa</surname> <given-names>EA</given-names></name><name><surname>Sirota-Madi</surname> <given-names>A</given-names></name><name><surname>Avila-Pacheco</surname> <given-names>J</given-names></name><name><surname>Fornelos</surname> <given-names>N</given-names></name><name><surname>Haiser</surname> <given-names>HJ</given-names></name><name><surname>Reinker</surname> <given-names>S</given-names></name><name><surname>Vatanen</surname> <given-names>T</given-names></name><name><surname>Hall</surname> <given-names>AB</given-names></name><name><surname>Mallick</surname> <given-names>H</given-names></name><name><surname>McIver</surname> <given-names>LJ</given-names></name><name><surname>Sauk</surname> <given-names>JS</given-names></name><name><surname>Wilson</surname> <given-names>RG</given-names></name><name><surname>Stevens</surname> <given-names>BW</given-names></name><name><surname>Scott</surname> <given-names>JM</given-names></name><name><surname>Pierce</surname> <given-names>K</given-names></name><name><surname>Deik</surname> <given-names>AA</given-names></name><name><surname>Bullock</surname> <given-names>K</given-names></name><name><surname>Imhann</surname> <given-names>F</given-names></name><name><surname>Porter</surname> <given-names>JA</given-names></name><name><surname>Zhernakova</surname> <given-names>A</given-names></name><name><surname>Fu</surname> <given-names>J</given-names></name><name><surname>Weersma</surname> <given-names>RK</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Clish</surname> <given-names>CB</given-names></name><name><surname>Vlamakis</surname> <given-names>H</given-names></name><name><surname>Huttenhower</surname> <given-names>C</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gut microbiome structure and metabolic activity in inflammatory bowel disease</article-title><source>Nature Microbiology</source><volume>4</volume><fpage>293</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0306-4</pub-id><pub-id pub-id-type="pmid">30531976</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouy</surname> <given-names>M</given-names></name><name><surname>Guindon</surname> <given-names>S</given-names></name><name><surname>Gascuel</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building</article-title><source>Molecular Biology and Evolution</source><volume>27</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1093/molbev/msp259</pub-id><pub-id pub-id-type="pmid">19854763</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grąz</surname> <given-names>M</given-names></name><name><surname>Rachwał</surname> <given-names>K</given-names></name><name><surname>Zan</surname> <given-names>R</given-names></name><name><surname>Jarosz-Wilkołazka</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oxalic acid degradation by a novel fungal oxalate oxidase from Abortiporus biennis</article-title><source>Acta Biochimica Polonica</source><volume>63</volume><elocation-id>1282</elocation-id><pub-id pub-id-type="doi">10.18388/abp.2016_1282</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>C-Q</given-names></name><name><surname>Shan</surname> <given-names>C-X</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>H-H</given-names></name><name><surname>Huang</surname> <given-names>Z-P</given-names></name><name><surname>Zou</surname> <given-names>D-J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gut Microbiota after Roux-en-Y gastric bypass and sleeve gastrectomy in a diabetic rat model: increased diversity and associations of discriminant genera with metabolic changes</article-title><source>Diabetes/Metabolism Research and Reviews</source><volume>33</volume><elocation-id>e2857</elocation-id><pub-id pub-id-type="doi">10.1002/dmrr.2857</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatch</surname> <given-names>M</given-names></name><name><surname>Cornelius</surname> <given-names>J</given-names></name><name><surname>Allison</surname> <given-names>M</given-names></name><name><surname>Sidhu</surname> <given-names>H</given-names></name><name><surname>Peck</surname> <given-names>A</given-names></name><name><surname>Freel</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion</article-title><source>Kidney International</source><volume>69</volume><fpage>691</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000162</pub-id><pub-id pub-id-type="pmid">16518326</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatch</surname> <given-names>M</given-names></name><name><surname>Gjymishka</surname> <given-names>A</given-names></name><name><surname>Salido</surname> <given-names>EC</given-names></name><name><surname>Allison</surname> <given-names>MJ</given-names></name><name><surname>Freel</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter</article-title><source>American Journal of Physiology-Gastrointestinal and Liver Physiology</source><volume>300</volume><fpage>G461</fpage><lpage>G469</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00434.2010</pub-id><pub-id pub-id-type="pmid">21163900</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoppe</surname> <given-names>B</given-names></name><name><surname>Groothoff</surname> <given-names>JW</given-names></name><name><surname>Hulton</surname> <given-names>SA</given-names></name><name><surname>Cochat</surname> <given-names>P</given-names></name><name><surname>Niaudet</surname> <given-names>P</given-names></name><name><surname>Kemper</surname> <given-names>MJ</given-names></name><name><surname>Deschênes</surname> <given-names>G</given-names></name><name><surname>Unwin</surname> <given-names>R</given-names></name><name><surname>Milliner</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria</article-title><source>Nephrology Dialysis Transplantation</source><volume>26</volume><fpage>3609</fpage><lpage>3615</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfr107</pub-id><pub-id pub-id-type="pmid">21460356</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoppe</surname> <given-names>B</given-names></name><name><surname>Niaudet</surname> <given-names>P</given-names></name><name><surname>Salomon</surname> <given-names>R</given-names></name><name><surname>Harambat</surname> <given-names>J</given-names></name><name><surname>Hulton</surname> <given-names>SA</given-names></name><name><surname>Van't Hoff</surname> <given-names>W</given-names></name><name><surname>Moochhala</surname> <given-names>SH</given-names></name><name><surname>Deschênes</surname> <given-names>G</given-names></name><name><surname>Lindner</surname> <given-names>E</given-names></name><name><surname>Sjögren</surname> <given-names>A</given-names></name><name><surname>Cochat</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A randomised phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria</article-title><source>Pediatric Nephrology</source><volume>32</volume><fpage>781</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1007/s00467-016-3553-8</pub-id><pub-id pub-id-type="pmid">27924398</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hylander</surname> <given-names>E</given-names></name><name><surname>Jarnum</surname> <given-names>S</given-names></name><name><surname>Jensen</surname> <given-names>HJ</given-names></name><name><surname>Thale</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Enteric hyperoxaluria: dependence on small intestinal resection, Colectomy, and steatorrhoea in chronic inflammatory bowel disease</article-title><source>Scandinavian Journal of Gastroenterology</source><volume>13</volume><fpage>577</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.3109/00365527809181767</pub-id><pub-id pub-id-type="pmid">705253</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hylander</surname> <given-names>E</given-names></name><name><surname>Jarnum</surname> <given-names>S</given-names></name><name><surname>Frandsen</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Urolithiasis and hyperoxaluria in chronic inflammatory bowel disease</article-title><source>Scandinavian Journal of Gastroenterology</source><volume>14</volume><fpage>475</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">482860</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>J</given-names></name><name><surname>Knight</surname> <given-names>J</given-names></name><name><surname>Easter</surname> <given-names>LH</given-names></name><name><surname>Neiberg</surname> <given-names>R</given-names></name><name><surname>Holmes</surname> <given-names>RP</given-names></name><name><surname>Assimos</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion</article-title><source>Journal of Urology</source><volume>186</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2011.03.006</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jowett</surname> <given-names>SL</given-names></name><name><surname>Seal</surname> <given-names>CJ</given-names></name><name><surname>Barton</surname> <given-names>JR</given-names></name><name><surname>Welfare</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>1. use of the simple clinical colitis activity index (SCCAI) TO define relapse of ulcerative colitis (UC)</article-title><source>Gut</source><volume>48</volume><fpage>A1</fpage><lpage>A5</lpage><pub-id pub-id-type="doi">10.1136/gut.48.suppl_1.A1</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminski</surname> <given-names>J</given-names></name><name><surname>Gibson</surname> <given-names>MK</given-names></name><name><surname>Franzosa</surname> <given-names>EA</given-names></name><name><surname>Segata</surname> <given-names>N</given-names></name><name><surname>Dantas</surname> <given-names>G</given-names></name><name><surname>Huttenhower</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High-Specificity targeted functional profiling in microbial communities with ShortBRED</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004557</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004557</pub-id><pub-id pub-id-type="pmid">26682918</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname> <given-names>JP</given-names></name><name><surname>Curhan</surname> <given-names>GC</given-names></name><name><surname>Cave</surname> <given-names>DR</given-names></name><name><surname>Anderson</surname> <given-names>TE</given-names></name><name><surname>Kaufman</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Factors related to colonization with Oxalobacter formigenes in U.S. adults</article-title><source>Journal of Endourology</source><volume>25</volume><fpage>673</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1089/end.2010.0462</pub-id><pub-id pub-id-type="pmid">21381959</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>SR</given-names></name><name><surname>Glenton</surname> <given-names>PA</given-names></name><name><surname>Byer</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline</article-title><source>Kidney International</source><volume>70</volume><fpage>914</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5001699</pub-id><pub-id pub-id-type="pmid">16850024</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharlamb</surname> <given-names>V</given-names></name><name><surname>Schelker</surname> <given-names>J</given-names></name><name><surname>Francois</surname> <given-names>F</given-names></name><name><surname>Jiang</surname> <given-names>J</given-names></name><name><surname>Holmes</surname> <given-names>RP</given-names></name><name><surname>Goldfarb</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes</article-title><source>Journal of Endourology</source><volume>25</volume><fpage>1781</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.1089/end.2011.0243</pub-id><pub-id pub-id-type="pmid">22017284</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimesova</surname> <given-names>K</given-names></name><name><surname>Whittamore</surname> <given-names>JM</given-names></name><name><surname>Hatch</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria</article-title><source>Urolithiasis</source><volume>43</volume><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1007/s00240-014-0728-2</pub-id><pub-id pub-id-type="pmid">25269440</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knauf</surname> <given-names>F</given-names></name><name><surname>Ko</surname> <given-names>N</given-names></name><name><surname>Jiang</surname> <given-names>Z</given-names></name><name><surname>Robertson</surname> <given-names>WG</given-names></name><name><surname>Van Itallie</surname> <given-names>CM</given-names></name><name><surname>Anderson</surname> <given-names>JM</given-names></name><name><surname>Aronson</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Net intestinal transport of oxalate reflects passive absorption and SLC26A6-mediated secretion</article-title><source>Journal of the American Society of Nephrology</source><volume>22</volume><fpage>2247</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1681/ASN.2011040433</pub-id><pub-id pub-id-type="pmid">22021714</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knauf</surname> <given-names>F</given-names></name><name><surname>Asplin</surname> <given-names>JR</given-names></name><name><surname>Granja</surname> <given-names>I</given-names></name><name><surname>Schmidt</surname> <given-names>IM</given-names></name><name><surname>Moeckel</surname> <given-names>GW</given-names></name><name><surname>David</surname> <given-names>RJ</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Aronson</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy</article-title><source>Kidney International</source><volume>84</volume><fpage>895</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1038/ki.2013.207</pub-id><pub-id pub-id-type="pmid">23739234</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kullin</surname> <given-names>B</given-names></name><name><surname>Tannock</surname> <given-names>GW</given-names></name><name><surname>Loach</surname> <given-names>DM</given-names></name><name><surname>Kimura</surname> <given-names>K</given-names></name><name><surname>Abratt</surname> <given-names>VR</given-names></name><name><surname>Reid</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A functional analysis of the formyl-coenzyme A (frc) gene from Lactobacillus reuteri 100-23C</article-title><source>Journal of Applied Microbiology</source><volume>116</volume><fpage>1657</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1111/jam.12500</pub-id><pub-id pub-id-type="pmid">24655128</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Ghoshal</surname> <given-names>UC</given-names></name><name><surname>Singh</surname> <given-names>G</given-names></name><name><surname>Mittal</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation</article-title><source>Journal of Gastroenterology and Hepatology</source><volume>19</volume><fpage>1403</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2004.03510.x</pub-id><pub-id pub-id-type="pmid">15610315</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Lieske</surname> <given-names>JC</given-names></name><name><surname>Collazo-Clavell</surname> <given-names>ML</given-names></name><name><surname>Sarr</surname> <given-names>MG</given-names></name><name><surname>Olson</surname> <given-names>ER</given-names></name><name><surname>Vrtiska</surname> <given-names>TJ</given-names></name><name><surname>Bergstralh</surname> <given-names>EJ</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery</article-title><source>Surgery</source><volume>149</volume><fpage>654</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2010.11.015</pub-id><pub-id pub-id-type="pmid">21295813</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname> <given-names>ZD</given-names></name><name><surname>Müller</surname> <given-names>CL</given-names></name><name><surname>Miraldi</surname> <given-names>ER</given-names></name><name><surname>Littman</surname> <given-names>DR</given-names></name><name><surname>Blaser</surname> <given-names>MJ</given-names></name><name><surname>Bonneau</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sparse and compositionally robust inference of microbial ecological networks</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004226</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004226</pub-id><pub-id pub-id-type="pmid">25950956</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname> <given-names>C</given-names></name><name><surname>Jeong</surname> <given-names>BC</given-names></name><name><surname>Ku</surname> <given-names>JH</given-names></name><name><surname>Kim</surname> <given-names>HH</given-names></name><name><surname>Lee</surname> <given-names>JJ</given-names></name><name><surname>Huh</surname> <given-names>CS</given-names></name><name><surname>Baek</surname> <given-names>YJ</given-names></name><name><surname>Lee</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Prevention of nephrolithiasis by Lactobacillus in stone-forming rats: a preliminary study</article-title><source>Urological Research</source><volume>34</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1007/s00240-006-0054-4</pub-id><pub-id pub-id-type="pmid">16633809</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Chatelier</surname> <given-names>E</given-names></name><name><surname>Nielsen</surname> <given-names>T</given-names></name><name><surname>Qin</surname> <given-names>J</given-names></name><name><surname>Prifti</surname> <given-names>E</given-names></name><name><surname>Hildebrand</surname> <given-names>F</given-names></name><name><surname>Falony</surname> <given-names>G</given-names></name><name><surname>Almeida</surname> <given-names>M</given-names></name><name><surname>Arumugam</surname> <given-names>M</given-names></name><name><surname>Batto</surname> <given-names>JM</given-names></name><name><surname>Kennedy</surname> <given-names>S</given-names></name><name><surname>Leonard</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Burgdorf</surname> <given-names>K</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Jørgensen</surname> <given-names>T</given-names></name><name><surname>Brandslund</surname> <given-names>I</given-names></name><name><surname>Nielsen</surname> <given-names>HB</given-names></name><name><surname>Juncker</surname> <given-names>AS</given-names></name><name><surname>Bertalan</surname> <given-names>M</given-names></name><name><surname>Levenez</surname> <given-names>F</given-names></name><name><surname>Pons</surname> <given-names>N</given-names></name><name><surname>Rasmussen</surname> <given-names>S</given-names></name><name><surname>Sunagawa</surname> <given-names>S</given-names></name><name><surname>Tap</surname> <given-names>J</given-names></name><name><surname>Tims</surname> <given-names>S</given-names></name><name><surname>Zoetendal</surname> <given-names>EG</given-names></name><name><surname>Brunak</surname> <given-names>S</given-names></name><name><surname>Clément</surname> <given-names>K</given-names></name><name><surname>Doré</surname> <given-names>J</given-names></name><name><surname>Kleerebezem</surname> <given-names>M</given-names></name><name><surname>Kristiansen</surname> <given-names>K</given-names></name><name><surname>Renault</surname> <given-names>P</given-names></name><name><surname>Sicheritz-Ponten</surname> <given-names>T</given-names></name><name><surname>de Vos</surname> <given-names>WM</given-names></name><name><surname>Zucker</surname> <given-names>JD</given-names></name><name><surname>Raes</surname> <given-names>J</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><collab>MetaHIT consortium</collab><name><surname>Bork</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Ehrlich</surname> <given-names>SD</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Richness of human gut microbiome correlates with metabolic markers</article-title><source>Nature</source><volume>500</volume><fpage>541</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nature12506</pub-id><pub-id pub-id-type="pmid">23985870</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Ellis</surname> <given-names>ML</given-names></name><name><surname>Knight</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Oxalobacter formigenes colonization and oxalate dynamics in a mouse model</article-title><source>Applied and Environmental Microbiology</source><volume>81</volume><fpage>5048</fpage><lpage>5054</lpage><pub-id pub-id-type="doi">10.1128/AEM.01313-15</pub-id><pub-id pub-id-type="pmid">25979889</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Ellis</surname> <given-names>ML</given-names></name><name><surname>Dowell</surname> <given-names>AE</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Morrow</surname> <given-names>CD</given-names></name><name><surname>Schoeb</surname> <given-names>TR</given-names></name><name><surname>Knight</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Response of germ-free mice to colonization with O. formigenes and altered schaedler flora</article-title><source>Applied and Environmental Microbiology</source><volume>82</volume><fpage>6952</fpage><lpage>6960</lpage><pub-id pub-id-type="doi">10.1128/AEM.02381-16</pub-id><pub-id pub-id-type="pmid">27663026</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieske</surname> <given-names>JC</given-names></name><name><surname>Rule</surname> <given-names>AD</given-names></name><name><surname>Krambeck</surname> <given-names>AE</given-names></name><name><surname>Williams</surname> <given-names>JC</given-names></name><name><surname>Bergstralh</surname> <given-names>EJ</given-names></name><name><surname>Mehta</surname> <given-names>RA</given-names></name><name><surname>Moyer</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Stone composition as a function of age and sex</article-title><source>Clinical Journal of the American Society of Nephrology</source><volume>9</volume><fpage>2141</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.2215/CJN.05660614</pub-id><pub-id pub-id-type="pmid">25278549</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>FindTaxaCtrbt</data-title><source>Software Heritage</source><version designator="swh:1:rev:13bbc4662f458bff327e348162bf51d875ed34d3">swh:1:rev:13bbc4662f458bff327e348162bf51d875ed34d3</version><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:b4d7dc8974adaca3e6ed9b9e7b1c8f8adf2e1741;origin=https://github.com/ml3958/FindTaxaCtrbt;visit=swh:1:snp:8f7fffcb012c57648cdb8a6b798abf40ec4d8050;anchor=swh:1:rev:13bbc4662f458bff327e348162bf51d875ed34d3/">https://archive.softwareheritage.org/swh:1:dir:b4d7dc8974adaca3e6ed9b9e7b1c8f8adf2e1741;origin=https://github.com/ml3958/FindTaxaCtrbt;visit=swh:1:snp:8f7fffcb012c57648cdb8a6b798abf40ec4d8050;anchor=swh:1:rev:13bbc4662f458bff327e348162bf51d875ed34d3/</ext-link></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Nazzal</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Enteric hyperoxaluria: role of Microbiota and antibiotics</article-title><source>Current Opinion in Nephrology and Hypertension</source><volume>28</volume><fpage>352</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1097/MNH.0000000000000518</pub-id><pub-id pub-id-type="pmid">31145706</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Price</surname> <given-names>J</given-names></name><name><surname>Arze</surname> <given-names>C</given-names></name><name><surname>Ananthakrishnan</surname> <given-names>AN</given-names></name><name><surname>Schirmer</surname> <given-names>M</given-names></name><name><surname>Avila-Pacheco</surname> <given-names>J</given-names></name><name><surname>Poon</surname> <given-names>TW</given-names></name><name><surname>Andrews</surname> <given-names>E</given-names></name><name><surname>Ajami</surname> <given-names>NJ</given-names></name><name><surname>Bonham</surname> <given-names>KS</given-names></name><name><surname>Brislawn</surname> <given-names>CJ</given-names></name><name><surname>Casero</surname> <given-names>D</given-names></name><name><surname>Courtney</surname> <given-names>H</given-names></name><name><surname>Gonzalez</surname> <given-names>A</given-names></name><name><surname>Graeber</surname> <given-names>TG</given-names></name><name><surname>Hall</surname> <given-names>AB</given-names></name><name><surname>Lake</surname> <given-names>K</given-names></name><name><surname>Landers</surname> <given-names>CJ</given-names></name><name><surname>Mallick</surname> <given-names>H</given-names></name><name><surname>Plichta</surname> <given-names>DR</given-names></name><name><surname>Prasad</surname> <given-names>M</given-names></name><name><surname>Rahnavard</surname> <given-names>G</given-names></name><name><surname>Sauk</surname> <given-names>J</given-names></name><name><surname>Shungin</surname> <given-names>D</given-names></name><name><surname>Vázquez-Baeza</surname> <given-names>Y</given-names></name><name><surname>White</surname> <given-names>RA</given-names></name><name><surname>Braun</surname> <given-names>J</given-names></name><name><surname>Denson</surname> <given-names>LA</given-names></name><name><surname>Jansson</surname> <given-names>JK</given-names></name><name><surname>Knight</surname> <given-names>R</given-names></name><name><surname>Kugathasan</surname> <given-names>S</given-names></name><name><surname>McGovern</surname> <given-names>DPB</given-names></name><name><surname>Petrosino</surname> <given-names>JF</given-names></name><name><surname>Stappenbeck</surname> <given-names>TS</given-names></name><name><surname>Winter</surname> <given-names>HS</given-names></name><name><surname>Clish</surname> <given-names>CB</given-names></name><name><surname>Franzosa</surname> <given-names>EA</given-names></name><name><surname>Vlamakis</surname> <given-names>H</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Huttenhower</surname> <given-names>C</given-names></name><collab>IBDMDB Investigators</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases</article-title><source>Nature</source><volume>569</volume><fpage>655</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1237-9</pub-id><pub-id pub-id-type="pmid">31142855</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manz</surname> <given-names>M</given-names></name><name><surname>Burri</surname> <given-names>E</given-names></name><name><surname>Rothen</surname> <given-names>C</given-names></name><name><surname>Tchanguizi</surname> <given-names>N</given-names></name><name><surname>Niederberger</surname> <given-names>C</given-names></name><name><surname>Rossi</surname> <given-names>L</given-names></name><name><surname>Beglinger</surname> <given-names>C</given-names></name><name><surname>Lehmann</surname> <given-names>FS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study</article-title><source>BMC Gastroenterology</source><volume>12</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1186/1471-230X-12-5</pub-id><pub-id pub-id-type="pmid">22233279</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname> <given-names>N</given-names></name><name><surname>Campbell</surname> <given-names>S</given-names></name><name><surname>Gillanders</surname> <given-names>I</given-names></name><name><surname>Rolton</surname> <given-names>H</given-names></name><name><surname>Danesh</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Risk factors for developing renal stones in inflammatory bowel disease</article-title><source>BJU International</source><volume>89</volume><fpage>835</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1046/j.1464-410X.2002.02739.x</pub-id><pub-id pub-id-type="pmid">12010224</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNally</surname> <given-names>CP</given-names></name><name><surname>Eng</surname> <given-names>A</given-names></name><name><surname>Noecker</surname> <given-names>C</given-names></name><name><surname>Gagne-Maynard</surname> <given-names>WC</given-names></name><name><surname>Borenstein</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BURRITO: an interactive Multi-Omic tool for visualizing Taxa-Function relationships in microbiome data</article-title><source>Frontiers in Microbiology</source><volume>9</volume><elocation-id>365</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.00365</pub-id><pub-id pub-id-type="pmid">29545787</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>AW</given-names></name><name><surname>Kohl</surname> <given-names>KD</given-names></name><name><surname>Dearing</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The gastrointestinal tract of the white-throated woodrat (Neotoma albigula) harbors distinct consortia of oxalate-degrading Bacteria</article-title><source>Applied and Environmental Microbiology</source><volume>80</volume><fpage>1595</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1128/AEM.03742-13</pub-id><pub-id pub-id-type="pmid">24362432</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname> <given-names>AL</given-names></name><name><surname>Attwood</surname> <given-names>TK</given-names></name><name><surname>Babbitt</surname> <given-names>PC</given-names></name><name><surname>Blum</surname> <given-names>M</given-names></name><name><surname>Bork</surname> <given-names>P</given-names></name><name><surname>Bridge</surname> <given-names>A</given-names></name><name><surname>Brown</surname> <given-names>SD</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>El-Gebali</surname> <given-names>S</given-names></name><name><surname>Fraser</surname> <given-names>MI</given-names></name><name><surname>Gough</surname> <given-names>J</given-names></name><name><surname>Haft</surname> <given-names>DR</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Letunic</surname> <given-names>I</given-names></name><name><surname>Lopez</surname> <given-names>R</given-names></name><name><surname>Luciani</surname> <given-names>A</given-names></name><name><surname>Madeira</surname> <given-names>F</given-names></name><name><surname>Marchler-Bauer</surname> <given-names>A</given-names></name><name><surname>Mi</surname> <given-names>H</given-names></name><name><surname>Natale</surname> <given-names>DA</given-names></name><name><surname>Necci</surname> <given-names>M</given-names></name><name><surname>Nuka</surname> <given-names>G</given-names></name><name><surname>Orengo</surname> <given-names>C</given-names></name><name><surname>Pandurangan</surname> <given-names>AP</given-names></name><name><surname>Paysan-Lafosse</surname> <given-names>T</given-names></name><name><surname>Pesseat</surname> <given-names>S</given-names></name><name><surname>Potter</surname> <given-names>SC</given-names></name><name><surname>Qureshi</surname> <given-names>MA</given-names></name><name><surname>Rawlings</surname> <given-names>ND</given-names></name><name><surname>Redaschi</surname> <given-names>N</given-names></name><name><surname>Richardson</surname> <given-names>LJ</given-names></name><name><surname>Rivoire</surname> <given-names>C</given-names></name><name><surname>Salazar</surname> <given-names>GA</given-names></name><name><surname>Sangrador-Vegas</surname> <given-names>A</given-names></name><name><surname>Sigrist</surname> <given-names>CJA</given-names></name><name><surname>Sillitoe</surname> <given-names>I</given-names></name><name><surname>Sutton</surname> <given-names>GG</given-names></name><name><surname>Thanki</surname> <given-names>N</given-names></name><name><surname>Thomas</surname> <given-names>PD</given-names></name><name><surname>Tosatto</surname> <given-names>SCE</given-names></name><name><surname>Yong</surname> <given-names>SY</given-names></name><name><surname>Finn</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>InterPro in 2019: improving coverage, classification and access to protein sequence annotations</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D351</fpage><lpage>D360</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1100</pub-id><pub-id pub-id-type="pmid">30398656</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname> <given-names>RD</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name><name><surname>Bid</surname> <given-names>HK</given-names></name><name><surname>Mittal</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Effect of antibiotics on Oxalobacter formigenes colonization of human gastrointestinal tract</article-title><source>Journal of Endourology</source><volume>19</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1089/end.2005.19.102</pub-id><pub-id pub-id-type="pmid">15735393</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogna</surname> <given-names>L</given-names></name><name><surname>Pane</surname> <given-names>M</given-names></name><name><surname>Nicola</surname> <given-names>S</given-names></name><name><surname>Raiteri</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans?</article-title><source>Journal of Clinical Gastroenterology</source><volume>48 Suppl 1</volume><fpage>S91</fpage><lpage>S95</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000000228</pub-id><pub-id pub-id-type="pmid">25291139</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulay</surname> <given-names>SR</given-names></name><name><surname>Kulkarni</surname> <given-names>OP</given-names></name><name><surname>Rupanagudi</surname> <given-names>KV</given-names></name><name><surname>Migliorini</surname> <given-names>A</given-names></name><name><surname>Darisipudi</surname> <given-names>MN</given-names></name><name><surname>Vilaysane</surname> <given-names>A</given-names></name><name><surname>Muruve</surname> <given-names>D</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Munro</surname> <given-names>F</given-names></name><name><surname>Liapis</surname> <given-names>H</given-names></name><name><surname>Anders</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion</article-title><source>Journal of Clinical Investigation</source><volume>123</volume><fpage>236</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1172/JCI63679</pub-id><pub-id pub-id-type="pmid">23221343</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulay</surname> <given-names>SR</given-names></name><name><surname>Desai</surname> <given-names>J</given-names></name><name><surname>Kumar</surname> <given-names>SV</given-names></name><name><surname>Eberhard</surname> <given-names>JN</given-names></name><name><surname>Thomasova</surname> <given-names>D</given-names></name><name><surname>Romoli</surname> <given-names>S</given-names></name><name><surname>Grigorescu</surname> <given-names>M</given-names></name><name><surname>Kulkarni</surname> <given-names>OP</given-names></name><name><surname>Popper</surname> <given-names>B</given-names></name><name><surname>Vielhauer</surname> <given-names>V</given-names></name><name><surname>Zuchtriegel</surname> <given-names>G</given-names></name><name><surname>Reichel</surname> <given-names>C</given-names></name><name><surname>Bräsen</surname> <given-names>JH</given-names></name><name><surname>Romagnani</surname> <given-names>P</given-names></name><name><surname>Bilyy</surname> <given-names>R</given-names></name><name><surname>Munoz</surname> <given-names>LE</given-names></name><name><surname>Herrmann</surname> <given-names>M</given-names></name><name><surname>Liapis</surname> <given-names>H</given-names></name><name><surname>Krautwald</surname> <given-names>S</given-names></name><name><surname>Linkermann</surname> <given-names>A</given-names></name><name><surname>Anders</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10274</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10274</pub-id><pub-id pub-id-type="pmid">26817517</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulay</surname> <given-names>SR</given-names></name><name><surname>Eberhard</surname> <given-names>JN</given-names></name><name><surname>Pfann</surname> <given-names>V</given-names></name><name><surname>Marschner</surname> <given-names>JA</given-names></name><name><surname>Darisipudi</surname> <given-names>MN</given-names></name><name><surname>Daniel</surname> <given-names>C</given-names></name><name><surname>Romoli</surname> <given-names>S</given-names></name><name><surname>Desai</surname> <given-names>J</given-names></name><name><surname>Grigorescu</surname> <given-names>M</given-names></name><name><surname>Kumar</surname> <given-names>SV</given-names></name><name><surname>Rathkolb</surname> <given-names>B</given-names></name><name><surname>Wolf</surname> <given-names>E</given-names></name><name><surname>Hrabě de Angelis</surname> <given-names>M</given-names></name><name><surname>Bäuerle</surname> <given-names>T</given-names></name><name><surname>Dietel</surname> <given-names>B</given-names></name><name><surname>Wagner</surname> <given-names>CA</given-names></name><name><surname>Amann</surname> <given-names>K</given-names></name><name><surname>Eckardt</surname> <given-names>KU</given-names></name><name><surname>Aronson</surname> <given-names>PS</given-names></name><name><surname>Anders</surname> <given-names>HJ</given-names></name><name><surname>Knauf</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice</article-title><source>American Journal of Physiology-Renal Physiology</source><volume>310</volume><fpage>F785</fpage><lpage>F795</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00488.2015</pub-id><pub-id pub-id-type="pmid">26764204</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulay</surname> <given-names>SR</given-names></name><name><surname>Eberhard</surname> <given-names>JN</given-names></name><name><surname>Desai</surname> <given-names>J</given-names></name><name><surname>Marschner</surname> <given-names>JA</given-names></name><name><surname>Kumar</surname> <given-names>SV</given-names></name><name><surname>Weidenbusch</surname> <given-names>M</given-names></name><name><surname>Grigorescu</surname> <given-names>M</given-names></name><name><surname>Lech</surname> <given-names>M</given-names></name><name><surname>Eltrich</surname> <given-names>N</given-names></name><name><surname>Müller</surname> <given-names>L</given-names></name><name><surname>Hans</surname> <given-names>W</given-names></name><name><surname>Hrabě de Angelis</surname> <given-names>M</given-names></name><name><surname>Vielhauer</surname> <given-names>V</given-names></name><name><surname>Hoppe</surname> <given-names>B</given-names></name><name><surname>Asplin</surname> <given-names>J</given-names></name><name><surname>Burzlaff</surname> <given-names>N</given-names></name><name><surname>Herrmann</surname> <given-names>M</given-names></name><name><surname>Evan</surname> <given-names>A</given-names></name><name><surname>Anders</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hyperoxaluria requires TNF receptors to initiate crystal adhesion and kidney stone disease</article-title><source>Journal of the American Society of Nephrology</source><volume>28</volume><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1681/ASN.2016040486</pub-id><pub-id pub-id-type="pmid">27612997</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname> <given-names>NJ</given-names></name><name><surname>Apweiler</surname> <given-names>R</given-names></name><name><surname>Attwood</surname> <given-names>TK</given-names></name><name><surname>Bairoch</surname> <given-names>A</given-names></name><name><surname>Bateman</surname> <given-names>A</given-names></name><name><surname>Binns</surname> <given-names>D</given-names></name><name><surname>Wu</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>InterPro, progress and status in 2005</article-title><source>Nucleic Acids Research</source><volume>33</volume><elocation-id>gki106</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gki106</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathirana</surname> <given-names>WGW</given-names></name><name><surname>Chubb</surname> <given-names>SP</given-names></name><name><surname>Gillett</surname> <given-names>MJ</given-names></name><name><surname>Vasikaran</surname> <given-names>SD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Faecal calprotectin</article-title><source>The Clinical Biochemist. Reviews</source><volume>39</volume><fpage>77</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">30828114</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>PeBenito</surname> <given-names>A</given-names></name><name><surname>Nazzal</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Jay</surname> <given-names>M</given-names></name><name><surname>Noya-Alarcon</surname> <given-names>O</given-names></name><name><surname>Contreras</surname> <given-names>M</given-names></name><name><surname>Lander</surname> <given-names>O</given-names></name><name><surname>Leach</surname> <given-names>J</given-names></name><name><surname>Dominguez-Bello</surname> <given-names>MG</given-names></name><name><surname>Blaser</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comparative prevalence of Oxalobacter formigenes in three human populations</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>574</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-36670-z</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pebenito</surname> <given-names>AM</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Nazzal</surname> <given-names>L</given-names></name><name><surname>Blaser</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Development of a humanized murine model for the study of Oxalobacter formigenes intestinal colonization</article-title><source>The Journal of Infectious Diseases</source><volume>220</volume><fpage>1848</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz370</pub-id><pub-id pub-id-type="pmid">31328778</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname> <given-names>LM</given-names></name><name><surname>Bautista</surname> <given-names>EJ</given-names></name><name><surname>Nguyen</surname> <given-names>H</given-names></name><name><surname>Hanson</surname> <given-names>BM</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Lek</surname> <given-names>SH</given-names></name><name><surname>Sodergren</surname> <given-names>E</given-names></name><name><surname>Weinstock</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Community characteristics of the gut microbiomes of competitive cyclists</article-title><source>Microbiome</source><volume>5</volume><elocation-id>98</elocation-id><pub-id pub-id-type="doi">10.1186/s40168-017-0320-4</pub-id><pub-id pub-id-type="pmid">28797298</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname> <given-names>E</given-names></name><name><surname>Becker</surname> <given-names>DF</given-names></name><name><surname>Ragsdale</surname> <given-names>SW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Identification and characterization of oxalate oxidoreductase, a novel thiamine pyrophosphate-dependent 2-oxoacid oxidoreductase that enables anaerobic growth on oxalate</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>40515</fpage><lpage>40524</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.155739</pub-id><pub-id pub-id-type="pmid">20956531</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rule</surname> <given-names>AD</given-names></name><name><surname>Lieske</surname> <given-names>JC</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Melton</surname> <given-names>LJ</given-names></name><name><surname>Krambeck</surname> <given-names>AE</given-names></name><name><surname>Bergstralh</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The ROKS nomogram for predicting a second symptomatic stone episode</article-title><source>Journal of the American Society of Nephrology</source><volume>25</volume><fpage>2878</fpage><lpage>2886</lpage><pub-id pub-id-type="doi">10.1681/ASN.2013091011</pub-id><pub-id pub-id-type="pmid">25104803</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saran</surname> <given-names>R</given-names></name><name><surname>Robinson</surname> <given-names>B</given-names></name><name><surname>Abbott</surname> <given-names>KC</given-names></name><name><surname>Agodoa</surname> <given-names>LYC</given-names></name><name><surname>Bhave</surname> <given-names>N</given-names></name><name><surname>Bragg-Gresham</surname> <given-names>J</given-names></name><name><surname>Balkrishnan</surname> <given-names>R</given-names></name><name><surname>Dietrich</surname> <given-names>X</given-names></name><name><surname>Eckard</surname> <given-names>A</given-names></name><name><surname>Eggers</surname> <given-names>PW</given-names></name><name><surname>Gaipov</surname> <given-names>A</given-names></name><name><surname>Gillen</surname> <given-names>D</given-names></name><name><surname>Gipson</surname> <given-names>D</given-names></name><name><surname>Hailpern</surname> <given-names>SM</given-names></name><name><surname>Hall</surname> <given-names>YN</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>K</given-names></name><name><surname>Herman</surname> <given-names>W</given-names></name><name><surname>Heung</surname> <given-names>M</given-names></name><name><surname>Hirth</surname> <given-names>RA</given-names></name><name><surname>Hutton</surname> <given-names>D</given-names></name><name><surname>Jacobsen</surname> <given-names>SJ</given-names></name><name><surname>Jin</surname> <given-names>Y</given-names></name><name><surname>Kalantar-Zadeh</surname> <given-names>K</given-names></name><name><surname>Kapke</surname> <given-names>A</given-names></name><name><surname>Kovesdy</surname> <given-names>CP</given-names></name><name><surname>Lavallee</surname> <given-names>D</given-names></name><name><surname>Leslie</surname> <given-names>J</given-names></name><name><surname>McCullough</surname> <given-names>K</given-names></name><name><surname>Modi</surname> <given-names>Z</given-names></name><name><surname>Molnar</surname> <given-names>MZ</given-names></name><name><surname>Montez-Rath</surname> <given-names>M</given-names></name><name><surname>Moradi</surname> <given-names>H</given-names></name><name><surname>Morgenstern</surname> <given-names>H</given-names></name><name><surname>Mukhopadhyay</surname> <given-names>P</given-names></name><name><surname>Nallamothu</surname> <given-names>B</given-names></name><name><surname>Nguyen</surname> <given-names>DV</given-names></name><name><surname>Norris</surname> <given-names>KC</given-names></name><name><surname>O'Hare</surname> <given-names>AM</given-names></name><name><surname>Obi</surname> <given-names>Y</given-names></name><name><surname>Park</surname> <given-names>C</given-names></name><name><surname>Pearson</surname> <given-names>J</given-names></name><name><surname>Pisoni</surname> <given-names>R</given-names></name><name><surname>Potukuchi</surname> <given-names>PK</given-names></name><name><surname>Rao</surname> <given-names>P</given-names></name><name><surname>Repeck</surname> <given-names>K</given-names></name><name><surname>Rhee</surname> <given-names>CM</given-names></name><name><surname>Schrager</surname> <given-names>J</given-names></name><name><surname>Schaubel</surname> <given-names>DE</given-names></name><name><surname>Selewski</surname> <given-names>DT</given-names></name><name><surname>Shaw</surname> <given-names>SF</given-names></name><name><surname>Shi</surname> <given-names>JM</given-names></name><name><surname>Shieu</surname> <given-names>M</given-names></name><name><surname>Sim</surname> <given-names>JJ</given-names></name><name><surname>Soohoo</surname> <given-names>M</given-names></name><name><surname>Steffick</surname> <given-names>D</given-names></name><name><surname>Streja</surname> <given-names>E</given-names></name><name><surname>Sumida</surname> <given-names>K</given-names></name><name><surname>Tamura</surname> <given-names>MK</given-names></name><name><surname>Tilea</surname> <given-names>A</given-names></name><name><surname>Tong</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Woodside</surname> <given-names>KJ</given-names></name><name><surname>Xin</surname> <given-names>X</given-names></name><name><surname>Yin</surname> <given-names>M</given-names></name><name><surname>You</surname> <given-names>AS</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Shahinian</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>US renal data system 2017 annual data report: epidemiology of kidney disease in the united states</article-title><source>American Journal of Kidney Diseases</source><volume>71</volume><elocation-id>A7</elocation-id><pub-id pub-id-type="doi">10.1053/j.ajkd.2018.01.002</pub-id><pub-id pub-id-type="pmid">29477157</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satsangi</surname> <given-names>J</given-names></name><name><surname>Silverberg</surname> <given-names>MS</given-names></name><name><surname>Vermeire</surname> <given-names>S</given-names></name><name><surname>Colombel</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications</article-title><source>Gut</source><volume>55</volume><fpage>749</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1136/gut.2005.082909</pub-id><pub-id pub-id-type="pmid">16698746</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname> <given-names>DR</given-names></name><name><surname>Sillery</surname> <given-names>J</given-names></name><name><surname>McDonald</surname> <given-names>GB</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Regional differences in oxalate absorption by rat intestine: evidence for excessive absorption by the Colon in steatorrhoea</article-title><source>Gut</source><volume>16</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1136/gut.16.7.543</pub-id><pub-id pub-id-type="pmid">1158192</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scales</surname> <given-names>CD</given-names></name><name><surname>Smith</surname> <given-names>AC</given-names></name><name><surname>Hanley</surname> <given-names>JM</given-names></name><name><surname>Saigal</surname> <given-names>CS</given-names></name><collab>Urologic Diseases in America Project</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Prevalence of kidney stones in the united states</article-title><source>European Urology</source><volume>62</volume><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.03.052</pub-id><pub-id pub-id-type="pmid">22498635</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirmer</surname> <given-names>M</given-names></name><name><surname>Franzosa</surname> <given-names>EA</given-names></name><name><surname>Lloyd-Price</surname> <given-names>J</given-names></name><name><surname>McIver</surname> <given-names>LJ</given-names></name><name><surname>Schwager</surname> <given-names>R</given-names></name><name><surname>Poon</surname> <given-names>TW</given-names></name><name><surname>Ananthakrishnan</surname> <given-names>AN</given-names></name><name><surname>Andrews</surname> <given-names>E</given-names></name><name><surname>Barron</surname> <given-names>G</given-names></name><name><surname>Lake</surname> <given-names>K</given-names></name><name><surname>Prasad</surname> <given-names>M</given-names></name><name><surname>Sauk</surname> <given-names>J</given-names></name><name><surname>Stevens</surname> <given-names>B</given-names></name><name><surname>Wilson</surname> <given-names>RG</given-names></name><name><surname>Braun</surname> <given-names>J</given-names></name><name><surname>Denson</surname> <given-names>LA</given-names></name><name><surname>Kugathasan</surname> <given-names>S</given-names></name><name><surname>McGovern</surname> <given-names>DPB</given-names></name><name><surname>Vlamakis</surname> <given-names>H</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Huttenhower</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dynamics of metatranscription in the inflammatory bowel disease gut microbiome</article-title><source>Nature Microbiology</source><volume>3</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/s41564-017-0089-z</pub-id><pub-id pub-id-type="pmid">29311644</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamatelou</surname> <given-names>KK</given-names></name><name><surname>Francis</surname> <given-names>ME</given-names></name><name><surname>Jones</surname> <given-names>CA</given-names></name><name><surname>Nyberg</surname> <given-names>LM</given-names></name><name><surname>Curhan</surname> <given-names>GC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Time trends in reported prevalence of kidney stones in the United States: 1976-1994</article-title><source>Kidney International</source><volume>63</volume><fpage>1817</fpage><lpage>1823</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00917.x</pub-id><pub-id pub-id-type="pmid">12675858</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname> <given-names>JM</given-names></name><name><surname>Moazami</surname> <given-names>S</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Kurland</surname> <given-names>I</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Agalliu</surname> <given-names>I</given-names></name><name><surname>Burk</surname> <given-names>R</given-names></name><name><surname>Davies</surname> <given-names>KP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers</article-title><source>Urolithiasis</source><volume>44</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1007/s00240-016-0882-9</pub-id><pub-id pub-id-type="pmid">27115405</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svedruzić</surname> <given-names>D</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Reinhardt</surname> <given-names>LA</given-names></name><name><surname>Wroclawska</surname> <given-names>E</given-names></name><name><surname>Cleland</surname> <given-names>WW</given-names></name><name><surname>Richards</surname> <given-names>NG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Investigating the roles of putative active site residues in the oxalate decarboxylase from <italic>Bacillus subtilis</italic></article-title><source>Archives of Biochemistry and Biophysics</source><volume>464</volume><fpage>36</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2007.03.016</pub-id><pub-id pub-id-type="pmid">17459326</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname> <given-names>A</given-names></name><name><surname>Bowater</surname> <given-names>L</given-names></name><name><surname>Fairhurst</surname> <given-names>SA</given-names></name><name><surname>Bornemann</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Oxalate decarboxylase requires manganese and dioxygen for activity. Overexpression and characterization of <italic>Bacillus subtilis</italic> YvrK and YoaN</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>43627</fpage><lpage>43634</lpage><pub-id pub-id-type="doi">10.1074/jbc.M107202200</pub-id><pub-id pub-id-type="pmid">11546787</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ticinesi</surname> <given-names>A</given-names></name><name><surname>Milani</surname> <given-names>C</given-names></name><name><surname>Guerra</surname> <given-names>A</given-names></name><name><surname>Allegri</surname> <given-names>F</given-names></name><name><surname>Lauretani</surname> <given-names>F</given-names></name><name><surname>Nouvenne</surname> <given-names>A</given-names></name><name><surname>Mancabelli</surname> <given-names>L</given-names></name><name><surname>Lugli</surname> <given-names>GA</given-names></name><name><surname>Turroni</surname> <given-names>F</given-names></name><name><surname>Duranti</surname> <given-names>S</given-names></name><name><surname>Mangifesta</surname> <given-names>M</given-names></name><name><surname>Viappiani</surname> <given-names>A</given-names></name><name><surname>Ferrario</surname> <given-names>C</given-names></name><name><surname>Dodi</surname> <given-names>R</given-names></name><name><surname>Dall'Asta</surname> <given-names>M</given-names></name><name><surname>Del Rio</surname> <given-names>D</given-names></name><name><surname>Ventura</surname> <given-names>M</given-names></name><name><surname>Meschi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Understanding the gut-kidney Axis in Nephrolithiasis: an analysis of the gut Microbiota composition and functionality of stone formers</article-title><source>Gut</source><volume>67</volume><fpage>2097</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-315734</pub-id><pub-id pub-id-type="pmid">29705728</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truong</surname> <given-names>DT</given-names></name><name><surname>Franzosa</surname> <given-names>EA</given-names></name><name><surname>Tickle</surname> <given-names>TL</given-names></name><name><surname>Scholz</surname> <given-names>M</given-names></name><name><surname>Weingart</surname> <given-names>G</given-names></name><name><surname>Pasolli</surname> <given-names>E</given-names></name><name><surname>Tett</surname> <given-names>A</given-names></name><name><surname>Huttenhower</surname> <given-names>C</given-names></name><name><surname>Segata</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MetaPhlAn2 for enhanced metagenomic taxonomic profiling</article-title><source>Nature Methods</source><volume>12</volume><fpage>902</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3589</pub-id><pub-id pub-id-type="pmid">26418763</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turroni</surname> <given-names>S</given-names></name><name><surname>Vitali</surname> <given-names>B</given-names></name><name><surname>Bendazzoli</surname> <given-names>C</given-names></name><name><surname>Candela</surname> <given-names>M</given-names></name><name><surname>Gotti</surname> <given-names>R</given-names></name><name><surname>Federici</surname> <given-names>F</given-names></name><name><surname>Pirovano</surname> <given-names>F</given-names></name><name><surname>Brigidi</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus</article-title><source>Journal of Applied Microbiology</source><volume>103</volume><fpage>1600</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2007.03388.x</pub-id><pub-id pub-id-type="pmid">17953571</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turroni</surname> <given-names>S</given-names></name><name><surname>Bendazzoli</surname> <given-names>C</given-names></name><name><surname>Dipalo</surname> <given-names>SC</given-names></name><name><surname>Candela</surname> <given-names>M</given-names></name><name><surname>Vitali</surname> <given-names>B</given-names></name><name><surname>Gotti</surname> <given-names>R</given-names></name><name><surname>Brigidi</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Oxalate-degrading activity in Bifidobacterium animalis subsp. lactis: impact of acidic conditions on the transcriptional levels of the oxalyl coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes</article-title><source>Applied and Environmental Microbiology</source><volume>76</volume><fpage>5609</fpage><lpage>5620</lpage><pub-id pub-id-type="doi">10.1128/AEM.00844-10</pub-id><pub-id pub-id-type="pmid">20601517</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waikar</surname> <given-names>SS</given-names></name><name><surname>Srivastava</surname> <given-names>A</given-names></name><name><surname>Palsson</surname> <given-names>R</given-names></name><name><surname>Shafi</surname> <given-names>T</given-names></name><name><surname>Hsu</surname> <given-names>CY</given-names></name><name><surname>Sharma</surname> <given-names>K</given-names></name><name><surname>Lash</surname> <given-names>JP</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Lieske</surname> <given-names>J</given-names></name><name><surname>Xie</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Feldman</surname> <given-names>HI</given-names></name><name><surname>Curhan</surname> <given-names>GC</given-names></name><collab>Chronic Renal Insufficiency Cohort study investigators</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Association of urinary oxalate excretion with the risk of chronic kidney disease progression</article-title><source>JAMA Internal Medicine</source><volume>179</volume><elocation-id>542</elocation-id><pub-id pub-id-type="doi">10.1001/jamainternmed.2018.7980</pub-id><pub-id pub-id-type="pmid">30830167</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63642.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Turnbaugh</surname><given-names>Peter</given-names></name><role>Reviewing Editor</role><aff><institution>University of California, San Francisco</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Dearing</surname><given-names>Denise</given-names></name><role>Reviewer</role><aff><institution>University of Utah</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Brown</surname><given-names>Eric</given-names></name><role>Reviewer</role><aff><institution>Broad Institute</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Oxalate is critical for kidney stones yet the bacteria responsible for its metabolism in humans remain poorly understood. Herein, the authors use a multi-disciplinary approach to study the abundance and expression of genes for human gut bacterial oxalate metabolism in healthy subjects and patients with inflammatory bowel disease. They go on to show that <italic>Oxalobacter formigenes</italic> significantly alters oxalate levels in mice. These analyses provide a critical step towards a more comprehensive view of oxalate metabolism and its role in health and disease.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Microbial contributions to oxalate metabolism in health and disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Wendy Garrett as the Senior Editor. The following individual involved in review of your submission have agreed to reveal their identity: Eric Brown (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>Liu and colleagues present a series of finding related to gut bacterial oxalate metabolism. First, they curate a set of previously described proteins and generate a reference database of homologs based upon Interpro annotations. Then, they re-analyze previously published meta-genomes and transcriptomes to find hits to these reference genes in the gut microbiomes of healthy and IBD subjects. Surprisingly, they find an inverse association between oxalate levels and the total transcripts of bacterial oxalate degradation genes. They also include data showing that <italic>Oxalobacter formigenes</italic> (a model oxalate degrading bacterium) impacts oxalate in mice. These analyses are a good example of how the microbiome field as a whole can utilize complex multi-omic datasets to help answer specific questions of clinical importance. However, there are multiple limitations and points which need to be addressed prior to publication.</p><p>Essential revisions</p><p>1. The claim that <italic>O. formigenes</italic> is the dominant oxalate degrading species is not well supported by any of the current data. The sequence analysis is based on a presumably partial knowledge of the full scope of enzymes capable of this activity, so it remains unclear if alternative species or pathways are important to consider. The mouse experiment is used as a &quot;validation&quot; but only shows that this species is sufficient to impact oxalate not that it is necessary in humans. A valuable first step would be to colonize germ-free mice with <italic>O. formigenes</italic> along with multiple other oxalate degraders, then perform leave-one-out experiments to test which species have a marked impact on oxalate levels when removed.</p><p>2. The approaches used to assign genes and species are not state-of-the-art and may not be entirely reliable. I'd suggest trying ShortBRED (Huttenhower lab) or a related tool to quantify the protein families of interest. FishTaco and BURRITO (Borenstein lab) could be used to help link taxonomy to function. This is an important point since it relates to the claim that <italic>O. formigenes</italic> is the source of most transcripts. Furthermore, it's unclear if these genes are horizontally transferred (which could be assessed by comparing gene and species trees). If so, simple read mapping could assign genes to the wrong genomes. Ignoring these other tools, the validation shown in Figure S3 doesn't make much sense to me. The threshold of 90% misses many of the intraspecies comparisons. I'm also concerned that Oxalobacter, the focus of this work, only has a handful of representative genes, which will make it difficult to reliably assign reads to this genus let alone to <italic>O. formigenes</italic> specifically.</p><p>3. Some attempt needs to be made to experimentally address the counter-intuitive observation that higher substrate (oxalate) is associated with lower expression, which runs counter to how most bacterial genes are regulated. What accounts for the downregulation? Is this related at all to the environment within the IBD gut?</p><p>4. The way the oxalate levels in the feces are presented is problematic. In the manuscript, the authors make multiple mentions the observed abundance of oxalate is a &quot;fecal concentration of oxalate&quot; when in fact it is the relative abundance of oxalate as measured by LC-MS. These data are not measuring concentration but relative abundance, which can be influenced by other non-biological factors such as how well the metabolite is ionized in each sample by LC-MS. Authors should not these are relative abundance calculations and not concentrations (for example Line 13 describing Figure 4A). Furthermore, the authors should indicate whether the samples were normalized between cohorts and how they were, and whether the relative abundance measurement is correct for within sample differences (% abundance of all observed metabolites) or a raw abundance? For example, the large difference between IBD and healthy stool could lead to less total metabolites being extracted and ionized thus data normalization between samples may actually increase the correlations you are seeing between oxalate and oxalate-degrading enzyme expression by meta-transcriptomics.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for submitting your article &quot;Microbial genetic and transcriptional contributions to oxalate degradation by the gut microbiota in health and disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Peter Turnbaugh as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Wendy Garrett as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. In Figure 4 the raw values in the y-axis when reporting oxalate relative abundance are unclear which units? Are they actually negative. The figure legends in general should include more specific information for the metabolomic data so it is easier to interpret.</p><p>2. The authors still refer to &quot;oxalate concentrations&quot; in the figure legend for figure 4.</p><p>3. It is unclear why the calprotectin cut-off was 50ug/mL please cite literature or a reason for using this value. It seems like there is in fact a trend with inflammation potentially.</p><p>4. Along that note Pearson analysis could show whether calprotectin levels correlate with Oxalobacter, something worth mentioning for the differences in abundance across IBD vs healthy controls and will be useful for the field if in fact this were to ever be utilized as a probiotic by others in the future.</p><p>5. More clarification is needed in the manuscript text on how comparing metagenomic analysis with metatranscriptomics can successfully pinpoint which taxa contribute to a disease pathway (in this case oxalate degradation). I still find this comparison confusing as a reader and potential pitfalls to this approach should be more clearly stated (sequencing depth as mentioned).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63642.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions</p><p>1. The claim that O. formigenes is the dominant oxalate degrading species is not well supported by any of the current data. The sequence analysis is based on a presumably partial knowledge of the full scope of enzymes capable of this activity, so it remains unclear if alternative species or pathways are important to consider. The mouse experiment is used as a &quot;validation&quot; but only shows that this species is sufficient to impact oxalate not that it is necessary in humans. A valuable first step would be to colonize germ-free mice with O. formigenes along with multiple other oxalate degraders, then perform leave-one-out experiments to test which species have a marked impact on oxalate levels when removed.</p></disp-quote><p>We agree with the reviewer that we do not know the full scope of enzymes capable of this activity, however we based our analysis and conclusions on the published literature, which indicates that oxalate degradation is through one of the 2 pathways (Figure 1). We now acknowledge this limitation in the Discussion.</p><p>We changed the description of the animal experiment to “To validate our bioinformatics prediction that <italic>Oxalobacter formigenes</italic> is an important oxalate degrading organism that can influence oxalate homeostasis in vivo, we examined whether the colonization of <italic>O. formigenes</italic> results in significant reduction in urinary oxalate in mice.”</p><p>We also thank the reviewer for the suggestion for a ‘leave-one-out’ experiment, which is in our future plans to test the hypothesis suggested by the data. We agree with the reviewer that an experiment in which we could give GF mice a synthetic community of potential oxalate-degrading microbes, and monitor their in vivo colonization, ODP transcription, and host oxalate metabolic responses will be valuable. However, such an experiment would require careful design and multiple pilot experiments. We would first need to test different diets of varying oxalate levels to establish a mouse model with intra-colonic oxalate concentrations faithfully mimicking the human intra-colonic milieu and avoiding toxicity to the oxalate-degrading community with high concentrations of dietary oxalate, as has been described (Miller, Dale et al. 2017). We also need to test multiple strains from the same species of oxalate degraders to ensure rigor. Thus, in combination with the current COVID situation limiting our capabilities to perform further animal experiments, we would like to argue that this current experiment is beyond the scope of this manuscript and propose to perform it when possible in the future, as part of a future manuscript. We have now added this limitation to the Discussion and the need for validating our results using animal models colonized with these different microbiota. We believe that the present manuscript has a number of important observations, not requiring this question to be answered, for it to still substantially advance the field.</p><disp-quote content-type="editor-comment"><p>2. The approaches used to assign genes and species are not state-of-the-art and may not be entirely reliable. The approaches used to assign genes and species are not state-of-the-art and may not be entirely reliable. I'd suggest trying ShortBRED (Huttenhower lab) or a related tool to quantify the protein families of interest.</p></disp-quote><p>As the reviewer suggested, we reanalyzed abundances of oxalate degrading enzymes (ODEs) using ShortBRED. First, using <italic>ShortBRED-identify</italic> default parameters, we clustered FRC, OXC, and OXDD homologs included in this study into 202, 190, and 846 families, respectively. Marker peptides were identified for each of the ODE protein families (see Methods). Next, using <italic>ShortBRED-quantify</italic>, we mapped the multi-omics reads of 2359 metagenomic and 1053 transcriptomic samples to those marker peptides and quantified abundances of each ODE using <italic>ShortBRED-quantify</italic>.</p><p>The results generated by these new <italic>ShortBRED</italic> analyses validated all of our prior major findings. We found that:</p><p>1. FRC and OXC, but not OXDD, are frequently detected in the human gut metagenome and metatranscriptome (New Figure 3—figure supplement 5A), which is consistent with our previous observation (Figure 3).</p><p><italic>2. O. formigenes</italic> is the species with the highest transcriptional activity for FRC (New Figure 3—figure supplement 5B). Specifically, each of the three <italic>O. formigenes</italic> FRC homologs (C3X9Y2, C3X762, and C3X2D4) are distinct from other homologs and from each other. Thus each formed a singleton family (New Supplementary file 2) with unique peptide markers (New Supplementary file 3). Based on the ShortBRED analysis, the three <italic>O. formigenes</italic> FRCs are the most commonly transcribed among the FRCs encoded by any taxon. They are present in the metatranscriptome of 50, 52, and 41 percent of the tested subjects, respectively (New Figure 3—figure supplement 5B, right), and also are among the most abundant ones (rank 1,2 and 5) among all FRC proteins (New Figure 3—figure supplement 5B, right). Therefore, <italic>O. formigenes</italic> is the dominant microbial source for FRC in the human microbiome (See below for OXC data).</p><p>3. Based on <italic>ShorBRED-quantify</italic> results, the global transcripts for <italic>frc</italic> and <italic>oxc</italic> are reduced in all IBD groups compared to healthy individuals, particularly in UC and CD-L3 IBD patients (New Figure 3—figure supplement 6), which is consistent with our previous observation (Figure 4).</p><p>However, ShortBRED relies on many arbitrary decisions (including CD-Hit, centroid protein selection, length and identity of short identical regions and final marker). It is not possible to empirically determine the best parameter combinations. For example, ShortBRED did not detect <italic>O. formigenes</italic> OXC in any sample, which contradicts all of our other analyses using ShortBRED and our method (Figure 3 and Figure 3—figure supplement 3), and contradicts the well-established fact that <italic>O. formigenes</italic> colonizes &gt;30% of humans (Kelly, Curhan et al. 2011, PeBenito, Nazzal et al. 2019). We reasoned that this under-detection is due to poorly-selected marker peptides. Indeed, the makers selected for the protein family of <italic>O. formigenes</italic> OXC (New Figure 3—figure supplement 6A, markers 1-20) are (1), short (median length 16.2 amino acids, as a comparison: the marker for <italic>O. formigenes</italic> FRC is 300 amino acids), and (2), improperly broken up from long continuous regions (New Figure 3—figure supplement 6A). Therefore, we manually generated new markers (Markers #21-24) by combining markers that were one amino acid apart. Using these longer markers, ShortBRED now successfully detected OXC using 3 of the 4 markers (except for the shortest marker) with the expected patterns (New Figure 3—figure supplement 6B, C).</p><p>ShortBRED and our previous method are different and both have unique strengths. Our previous method uses protein full length information and is completely agnostic, relying on best alignment hit to assign read to reference. Our method successfully detected <italic>O. formigenes</italic> FRC and OXC (Figure 3 and Figure 3—figure supplement 3). Thus, the two methods have different advantages and are complementary.</p><p>In summary, using a different methodology, several of our major conclusions were confirmed. We now report the results in the revised manuscript in the Results section <italic>Validation of ODP detection using ShortBRED</italic> and in New Figure 3—figure supplement 5, Figure 3—figure supplement 6. We also discuss the pros and cons of the two methods to help readers interpret the data.</p><disp-quote content-type="editor-comment"><p>FishTaco and BURRITO (Borenstein lab) could be used to help link taxonomy to function.</p></disp-quote><p>Thank you for this excellent suggestion. We now used BURRITO (McNally, Eng et al. 2018) to link function to taxa based on the taxonomic composition generated by Metaphlan2 (Truong, Franzosa et al. 2015) (See Methods). Only metagenomes (n=2359 samples) were included for this analysis because the method was designed to be used with metagenomic data in which the taxonomic and gene abundance are linearly linked.</p><p>The taxonomic contributions based on BURRITO (New Supplementary file 1d) are highly concordant with the findings using our original method (Supplementary file 1b, metagenome, Healthy). <italic>E. coli</italic> and <italic>O. formigenes</italic> are consistently the top two contributors, and several <italic>Bifidobacterium</italic> spp and <italic>Lactobacillus</italic> spp contributed to a lesser extent. We now added those new results into the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Furthermore, it's unclear if these genes are horizontally transferred (which could be assessed by comparing gene and species trees). If so, simple read mapping could assign genes to the wrong genomes.</p></disp-quote><p>The reviewers’ concern regarding horizontal gene transfer (HGT) is well-taken. FRC and OXC homologs encoded by the same Class of bacteria generally cluster together (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>), suggesting this pathway is evolutionary conserved at high taxonomic levels. As microbiomes are highly individual-specific, to address HGT, one needs to assemble reads from each metagenome to highquality contigs to provide fine resolution to assess for HGT. Currently such a task is technically and computationally challenging. As it is not the focus of current study, we acknowledge these limitations and now include the following sentence in the Discussion:</p><p>“The fact that we only used sequences of proteins instead of whole genomes during read mapping could lead to false taxonomic assignments due to possible horizontal gene transfer events”</p><fig id="respfig1"><label>Author response image 1.</label><caption><title>Phylogenetic analysis of OXC (A), FRC (B) uniref100 proteins.</title><p>Each tip represents a protein homolog, which is color-coded by the microbial Class associated with the encoding. The tip size is proportional to the prevalence of the corresponding protein in the metatranscriptomes of 165 healthy individuals. Homologs with prevalence &gt;1% are annotatedwith text.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-resp-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>I'm also concerned that Oxalobacter, the focus of this work, only has a handful of representative genes, which will make it difficult to reliably assign reads to this genus let alone to O. formigenes specifically.</p></disp-quote><p>We thank the reviewer for raising this concern. First, <italic>Oxalobacter</italic> is currently a small genus consisting of only two known species (The other species <italic>Oxalobacter vibrioformis</italic> was isolated from anoxic freshwater sediment and only described once in 1989 (Dehning and Schink 1989). Thus, we are confident that both <italic>Oxalobacter</italic> genus and <italic>O. formigenes</italic> species are highly-identifiable taxa. Second, the <italic>frc</italic> and <italic>oxc</italic> genes of <italic>O. formigenes</italic> species are distant from other species, as evidenced by the fact that ShortBRED CD Hit clustered them as individual families at the amino acid level) (New Supplementary file 2). Especially for FRC, all sequenced <italic>O. formigenes</italic> genomes encode three copies of the <italic>frc</italic> gene with conserved operon structures (<xref ref-type="fig" rid="respfig2">Author response image 2A</xref>). The three <italic>frc</italic> genes are further grouped into two forms (<xref ref-type="fig" rid="respfig2">Author response image 2B</xref>), both of which were identified in the current study. Collectively, the <italic>O. formigenes frc</italic> and <italic>oxc</italic> genes in our study are highly representative, and the read assignments for them should be highly specific as well.</p><fig id="respfig2"><label>Author response image 2.</label><caption><title>Operon structure and phylogenetic relationship of FRCs of four <italic>O.formigenes</italic> strains OXCC13, HC1, HOxBLS, and OXK, for which whole genome sequence is available.</title><p>(A). Schematic representation of the operon structures for the three FRC genes. The structures are conserved across all four strains. We named the three FRCs as α-, β-, and γ-FRC (from top to bottom). (B). Maximum likelihood phylogenetic tree for the α-, β-, and γ-FRCs from four <italic>O. formigenes</italic> strains, based on their amino acid sequence. The sequence alignment and tree were generated using phylogeny.fr using “simple click” mode.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63642-resp-fig2-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>The threshold of 90% misses many of the intraspecies comparisons.</p></disp-quote><p>We thank the reviewer for this comment. The 90% cutoff on an alignment hit is to prevent non-ODE reads being aligned to our ODE reference proteins at a low identity score. We now clarify this point in the text, as follows:</p><p>“By setting a stringent identity cutoff of 90%, we retain only the high confidence alignment pairs. The finding generated using this 90% cutoff is consistent with the observations generated through a second method ShortBRED, which uses ODE-specific marker peptides, which provide evidence that the cutoff is highly effective at preventing spurious alignment.”</p><disp-quote content-type="editor-comment"><p>3. Some attempt needs to be made to experimentally address the counter-intuitive observation that higher substrate (oxalate) is associated with lower expression, which runs counter to how most bacterial genes are regulated. What accounts for the downregulation?</p></disp-quote><p>The Reviewer is correct, and we thank him/her for the comment. The ‘downregulation’ of <italic>oxc</italic> or <italic>frc</italic> expression by microbiome referred to the reduction of total transcripts associated with <italic>oxc</italic> and <italic>frc</italic>. The suppression or absence of <italic>O. formigenes</italic> cells is largely responsible for the decrease in ODP transcripts in the IBD gut (Figure 5A). To avoid confusion, we have revised our manuscript, replacing “downregulation of ODP” with “global reduction of ODP-related transcripts” throughout.</p><disp-quote content-type="editor-comment"><p>Is this related at all to the environment within the IBD gut?</p></disp-quote><p>IBD patients regularly receive antibiotics, and <italic>O. formigenes</italic> is susceptible to commonly used antibiotics (Mittal, Kumar et al. 2005, Kharlamb, Schelker et al. 2011, Lange, Wood et al. 2012, Liu, Koh et al. 2017). Our unpublished human data in healthy adults (in revision, 2021) demonstrated that a single course of antibiotics (clarithromycin and metronidazole) to eradicate <italic>Helicobacter pylori</italic> results in the persistent suppression of <italic>O. formigenes</italic> colonization for at least 6 months. Other changes in the intestinal milieu of IBD patients affecting pH, oxygen levels, and increasing bile acids, have been shown to impact <italic>O. formigenes</italic> in vitro (Allison, Dawson et al. 1985, Duncan, Richardson et al. 2002). We have now added these potential explanations into the Discussion.</p><disp-quote content-type="editor-comment"><p>4. The way the oxalate levels in the feces are presented is problematic. In the manuscript, the authors make multiple mentions the observed abundance of oxalate is a &quot;fecal concentration of oxalate&quot; when in fact it is the relative abundance of oxalate as measured by LC-MS. These data are not measuring concentration but relative abundance, which can be influenced by other non-biological factors such as how well the metabolite is ionized in each sample by LC-MS. Authors should not these are relative abundance calculations and not concentrations (for example Line 13 describing Figure 4A). Furthermore, the authors should indicate whether the samples were normalized between cohorts and how they were, and whether the relative abundance measurement is correct for within sample differences (% abundance of all observed metabolites) or a raw abundance? For example, the large difference between IBD and healthy stool could lead to less total metabolites being extracted and ionized thus data normalization between samples may actually increase the correlations you are seeing between oxalate and oxalate-degrading enzyme expression by meta-transcriptomics.</p></disp-quote><p>We thank the Reviewer for these helpful comments. We address the Reviewer’s comment point-by-point below:</p><disp-quote content-type="editor-comment"><p>Authors should note these are relative abundance calculations and not concentrations (for example Line 13 describing Figure 4A). Furthermore, the authors should indicate whether the samples were normalized between cohorts and how they were, and whether the relative abundance measurement is correct for within sample differences (% abundance of all observed metabolites) or a raw abundance?</p></disp-quote><p>We thank the reviewer for this comment. As suggested, we have repeated all analyses based on the relative abundance of oxalate (% abundance of all observed metabolites in each sample), to account for sample differences (New Figure 4, which replaces the prior Figure 4). This point now is indicated in the Methods under section Meta-omics data of the human microbiome.</p><p>Using relative abundance, we reached the same observation that fecal oxalate is elevated in all IBD cohorts compared to healthy individuals (New Figure 4). The correlation between <italic>oxc</italic> expression and oxalate relative abundance showed negative, but not statistically significant, trends in all IBD groups (New Figure 4—figure supplement 4A), but <italic>frc</italic> was significantly inversely correlated with oxalate relative abundance in the UC group (New Figure 4—figure supplement 4A). In the revised manuscript, we now report the results based on both absolute and relative abundances.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. In Figure 4 the raw values in the y-axis when reporting oxalate relative abundance are unclear which units? Are they actually negative. The figure legends in general should include more specific information for the metabolomic data so it is easier to interpret.</p></disp-quote><p>As requested by a prior reviewer (Prior Review point 4), Figure 4A reports log<sub>10</sub> relative abundance of oxalate as a percent of the total metabolites measured (See Methods). The negative values are due to log<sub>10</sub> transformations as indicated in the figure. To improve clarity, we now include that information in the figure legend as follows:</p><p>“(A). Stool oxalate relative abundance (log<sub>10</sub>) in healthy, UC, CD, CD-L3 or CD-nonL3 subjects from the HMP-IBD study. Fecal oxalate relative abundance was determined from untargeted metabolomics data from iHMP-IBD; measurements related to oxalate were normalized against total metabolites (percent abundance of all observed metabolites) for analysis.”</p><disp-quote content-type="editor-comment"><p>2. The authors still refer to &quot;oxalate concentrations&quot; in the figure legend for figure 4.</p></disp-quote><p>We thank the reviewer for catching this error. We now have updated the figure axis and legend of Figure 4 and the related Supplemental Figures 1, 2, 4, and 5 to indicate “Fecal oxalate log<sub>10</sub> relative abundance”.</p><disp-quote content-type="editor-comment"><p>3. It is unclear why the calprotectin cut-off was 50ug/mL please cite literature or a reason for using this value. It seems like there is in fact a trend with inflammation potentially.</p></disp-quote><p>The fecal calprotectin cutoff was determined based on the pertinent literature (Damms and Bischoff, 2008; Manz et al., 2012; Pathirana, Chubb, Gillett, and Vasikaran, 2018) and to be consistent with current test kits (Pathirana et al., 2018). We have now included citations to these references in the main text and in the Figure Legend.</p><p>As the Editor/reviewer points out, increased fecal oxalate with higher inflammation levels (fecal calprotectin &gt;50µg/g) is indeed present. A sub-analysis with samples with fecal calprotectin &gt; 50ug/ml showed a positive correlation between fecal calprotectin and oxalate (new Figure 4—figure supplement 2C), which needs to be examined with larger patient cohorts in future studies. This point now is included in the text, as “We observed increased fecal oxalate in association with higher inflammation levels (fecal calprotectin &gt;50µg/ml) (Figure 4—figure supplement 2C); since our number of study subjects was small, this relationshp needs to be examined with larger patient cohorts in future studies.”</p><disp-quote content-type="editor-comment"><p>4. Along that note Pearson analysis could show whether calprotectin levels correlate with Oxalobacter, something worth mentioning for the differences in abundance across IBD vs healthy controls and will be useful for the field if in fact this were to ever be utilized as a probiotic by others in the future.</p></disp-quote><p>We agree, thank you. Using detection of <italic>O. formigenes</italic> ODP genes and transcripts jointly as a marker for its presence, we observed significantly elevated fecal calprotectin levels when <italic>O. formigenes</italic> is absent in healthy individuals and in CD-L3 patients. This analysis suggests that colonization by <italic>O. formigenes</italic> and gut inflammation could potentially be linked. As suggested by the Editor, we now include new Supplemental Figure 2D, which shows the relationship of <italic>O. formigenes</italic> status and fecal calprotectin level, without using an arbitrary cut-off. Although we show this Figure, we indicate that the underlying mechanism is unknown and needs to be examined in future studies. The new text that we have included is as follows: “Significantly elevated fecal calprotectin levels were observed when <italic>O. formigenes</italic> was absent in healthy individuals and in CD-L3 patients (Figure 4—figure supplement 2D) “</p><disp-quote content-type="editor-comment"><p>5. More clarification is needed in the manuscript text on how comparing metagenomic analysis with metatranscriptomics can successfully pinpoint which taxa contribute to a disease pathway (in this case oxalate degradation). I still find this comparison confusing as a reader and potential pitfalls to this approach should be more clearly stated (sequencing depth as mentioned).</p></disp-quote><p>We appreciate the reviewer’s suggestion. We now more clearly describe the two critical advantages of an approach that co-analyzes metagenome and metatranscriptome in the discussion, as follows:</p><p>“(1) Detection of genes in the metagenome does not ensure that they are being actively utilized by the indicated taxon. Thus, analyzing metatranscriptomic data allows distinguishing the taxa that are actively contributing to a biological process by generating the relevant proteins. In contrast, for those taxa that are not, the analysis provides a new view of their metabolism, in that although they have the potential for using a certain pathway or metabolite, it is not active under the particular condition tested. (2) Having metatranscriptomic data or other functional readout is particularly useful for cross-comparisons of the microbiome of different cohorts (i.e., diseased versus healthy subjects, in humans or experimental animals). For example, in our study, ODP genes were increased in IBD patients, whereas transcripts were significantly reduced. Specifically, the increased ODP gene abundances were due to the over-representation in IBD patients of <italic>E. coli</italic> strains that uncommonly transcribe ODP in vivo. In contrast, the decrease of oxalate-degrading gene expression is caused by the loss of <italic>O. formigenes</italic>, which is the dominant microbe that transcribes this pathway. Having observed the differential abundance for a gene does not necessarily indicate functional shifts, as gene abundance is driven by the most abundant taxa, which could be transcriptionally silent. As such, the transcriptional evidence is a better indicator for evaluation of microbiome functional differences.”</p><p>In addition to the previous description of the limitations of our methods, we now have added another limitation that “it is more difficult to acquire high-quality metatranscriptome, as RNA is less stable and subject to degradation during sample preparation”.</p><p>[Editors' note: we include below the reviews that the authors received from another journal, along with the authors’ responses.]</p><disp-quote content-type="editor-comment"><p>Reviewer 1</p><p>The authors have taken advantage of accrued data associated with the Microbiome Project to identify gut microbes in humans that are involved in the breakdown of oxalate. They importantly and for the first time use both metagenomics and metatranscriptomics to better understand microbial contributions to oxalate degradation in the human gut. They also performed analyses in various types of IBD to determine if these patients have perturbations of the oxalate degrading microbiome. Some novel aspects of the study were (1) classifying the abundance of oxalatedegrading organisms based on the enzymes involved and their co-factor requirements (2) revealing that the contribution of the oxalate auxotroph O. formigenes to the oxalate degrading pathway is greater than the transcriptomic contributions of all other species combined (3) demonstrating that oxalate degradation pathways were reduced and fecal oxalate elevated in patients with IBD compared with healthy controls. This study opens the doorway to the development of strategies that may off-set the increased oxalate absorption associated with IBD.</p></disp-quote><p>We appreciate the reviewer’s comment on the multiple novel aspects of the study. We agree that as the first systemic study on oxalate-degradation by human gut microbes, this work will open new avenues of therapeutic strategies for enteric hyperoxaluria (EH). This study for the first time describes the relative importance of different microbial taxa in human oxalate degradation, and identifies the most relevant clinical indication (Crohn’s disease with the ileocolonic phenotype).</p><disp-quote content-type="editor-comment"><p>Points that should be addressed:</p><p>1. Figure 4- Indicate if this is a log scale.</p></disp-quote><p>Thank you for this suggestion. The fecal oxalate level in panels A and D was on a log<sub>10</sub> scale, but this was not reflected on the axis title. We now have updated the axis title as “Log<sub>10</sub> fecal oxalate by LC-MS” (please see new Figure 4 on page 37).</p><p>2. Due to the importance of fecal oxalate measurements, the authors should add to their limitations that a more refined and targeted direct measure of fecal oxalate is warranted to substantiate these claims.</p><p>Thank you for the suggestion. We have now added a sentence in the Discussion section that states “In addition to the untargeted metabolomics data used in this study, targeted measurement of fecal and urinary oxalate is desired in future controlled human studies.”.</p><p>In addition, in a mouse experiment that we now present, both fecal and urine oxalate levels were directly measured using targeted assays (please see the new Figure 6B and Figure 6C on page 39).</p><p>3. Figure S10 (B). Legend indicates OXC abundance, but axis title is frc.</p><p>Thank you for pointing out this error. We now have updated that figure (see page 54).</p><disp-quote content-type="editor-comment"><p>Reviewer 2</p><p>The analysis is overall well done and convincing.</p></disp-quote><p>We thank the reviewer for the positive feedback.</p><disp-quote content-type="editor-comment"><p>1. Inflammasome pathways have been implicated but may not be the only mechanism of renal damage in hyperoxaluria.</p></disp-quote><p>Thank you for the comment. We agree with the reviewer that there are other mechanisms of calcium oxalate nephrotoxicity. Due to the word limits, we did not list all relevant studies. Now we have added text to the Introduction about other potential mechanisms of calcium oxalate nephrotoxicity.</p><disp-quote content-type="editor-comment"><p>2. There is no direct evidence that elevated intestinal oxalate is key to EH, although there us indirect evidence, especially in older literature from the 1980s</p></disp-quote><p>We thank the reviewer for this comment. We agree that there is no direct evidence yet linking fecal oxalate to EH. However, in prior EH human studies and animal models, fecal oxalate was not measured. In our study, we observed increased fecal oxalate in ulcerative colitis patients and Crohn’s disease patients with the ileocolonic phenotype, which is the same subgroups as have clinical nephrolithiasis risk (Cury, Moss, and Schor, 2013), suggesting that intestinal oxalate could be a marker for EH. In our mouse model, fecal and urine oxalate tended to correlate (please see new Figure 6D on page 39).</p><disp-quote content-type="editor-comment"><p>3. Lack of Urine oxalate data in these patients is a major weakness, and should be stressed more in the discussion1</p></disp-quote><p>We thank the reviewer for this comment. As above, we now provide mouse data on oxalate levels (new Figure 6 on page 39), which addresses the weakness pointed out by the reviewer.</p><disp-quote content-type="editor-comment"><p>Also, this limitation is stated in the Discussion as: “we did not have access to urinary oxalate or ascertain kidney stone history in our human IBD cohort, both critical variables to extend our conclusions”. However, previous studies have shown that intestinal oxalate is predominantly absorbed paracellularly <italic>(Binder, 1974; Knauf et al., 2011; Saunders, Sillery, and McDonald, 1975)</italic> along its concentration gradient; as such, colonic oxalate levels should correlate with both renal oxalate and with risk for CaOx stones.</p><p>4. It is interesting that the oxalate degrading taxa and genes are reduced in patients at risk for EH, despite the metabolomics data that fecal oxalate is increased. This merits some discussion</p></disp-quote><p>We thank the reviewer for this comment. In patients at risk for EH, the abundance of ODP genes is increased (Figure S10), but the extent of gene expression is decreased (Figure 4). This contrast between gene abundance and expression is due to differential ODP transcription in particular microbes. Specifically, the increase of ODP gene abundances was due to the overrepresentation of <italic>E. coli</italic> that rarely transcribe ODP in vivo. In contrast, the decrease of ODP-gene expression is caused by loss of <italic>O. formigenes</italic>, which is the dominant microbe that transcribes this pathway. This point is now clarified in the Discussion.</p><disp-quote content-type="editor-comment"><p>5. There is no good evidence that oral Oxalobacter could be used to recolonize EH patients, or would effectively reduce urinary oxalate. This part of the discussion should be more guarded</p></disp-quote><p>We thank the reviewer for this comment. We agree that <italic>O. formigenes</italic> colonization in EH patients needs to be established in future studies. However, in EH, the intestinal lumen is an oxalate-rich environment, which supports <italic>O. formigenes</italic> colonization and oxalate degradation prior to absorption into the host circulation. Furthermore, a recent study (Canales and Hatch, 2017) of a surgery-induced EH rat model via Roux-en-Y gastric bypass (RYGB), indicated the potential of <italic>O. formigenes</italic> for treating EH. in the post-RYGB rat, <italic>O. formigenes</italic> strain OXWR achieved 100% colonization and decreased urinary oxalate by 74% compared to 39% in the sham-operated group.</p><p>As the reviewer suggested, we now have added both points into the Discussion.</p><disp-quote content-type="editor-comment"><p>Minor comment</p><p>1. Be consistent in use of calcium-oxalate vs calcium oxalate. I would favor not using the hyphen.</p></disp-quote><p>Thank you. We have deleted the hyphen in “calcium-oxalate” throughout the manuscript, and changes are tracked in the document.</p><disp-quote content-type="editor-comment"><p>Reviewer 3</p><p>In the manuscript entitled “Microbial contributions to oxalate metabolism in health and disease”, Liu et al. have performed a meta-analysis of human fecal multi’omics datasets focusing on describing the gene abundance and expression of oxalate degradation pathway (OPD) genes across these data sets, including IBD cohorts.</p><p>The authors introduce the background and significance of this study highlighting that oxalate (systemic) toxicity is of significant importance as a risk factor of kidney stones and CKD. The authors then introduce that humans lack ODP but that gut microbes do, but that there are “gaps in our understanding of the role of the microbiota in diseases induced by oxalate toxicity”. The goals of the manuscript were to characterize ODP in human gut metagenomes and metatranscriptomes using pre-existing data sets.</p><p>In Ffigure 1, the authors search gut metagenomes for genes in type 1 or type 2 ODPs and assign to microbial taxa. The main conclusion is that type I genes occur in both bacteria and fungi, type I only in bacteria. In Figure 2, the authors then show that most human gut samples have ODP genes and that type II genes are much more prevalent that type I. Focusing on type 2 ODP, in Figure 3 the authors then assign type 2 ODP genes to various bacterial taxa, mostly belonging to <italic>E. coli</italic> (Ec) and Oxalobacter formigenes (Of). Comparing metagenomics (MGX) and metatranscriptomics (MTX), the authors show that while for Of, gene content and transcript correlated, for Ec transcript as not often detected and that transcript were dominated in MTX by</p><p>Of. The authors then in Figure 4 analyze data from IBD case and control cohorts (iHMP-IBD study), show that oxalate concentrations are higher in feces from people with IBD than control. Finally, in IBD compared to controls, the authors find decreased expression of type II ODP in IBD compared to controls. The reduced expression of ODP genes in IBD was assigned to Of (Figure 5).</p><p>General Commentary</p><p>The goals of this study characterizing ODP in human gut metagenomes and metatranscriptomes were met. This referee cannot formally critique the multi-omics methods or approach as not my area of expertise. I will critique this at the level of the novelty of the conclusions from this study, rather than a technical critique. There have been a number of microbiome compositional analysis associating oxalate nephrocalcinosis known of which were cited and this lack of citation misrepresents the field. The assignment of ODP genes to various taxa is a first comprehensive bioinformatics analysis, but not entirely novel, i.e. that organisms known to have this pathway were identified. The finding that ODP transcripts are dominated by Of compared to Ec is again “new” information but not necessarily unexpected as Of has an obligate requirement for oxalate and thus must express ODP genes for survival while Ec does not.</p></disp-quote><p>We appreciate the reviewer’s comments. Although we agree that some oxalatedegrading microbes have been individually characterized in vitro before, we believe our study provided novel insights with more depth and breadth, based on the following ideas:</p><p>1. We analyzed six ODPs that belong to two distinct types, and reached the novel conclusion that type I ODPs are encoded by both fungi and bacteria, but type II is exclusively encoded by bacteria, and that the human microbiome is associated with type II ODP.</p><p>2. Our study focuses on transcription of multiple oxalate-degrading enzymes in vivo using metatranscriptomics data. Such transcriptional evidence directly informs the functional potential of microbiota oxalate degradation. In contrast, the previous “microbiome compositional analysis” mentioned by the reviewer focused on microbiome population differences based on genetic-level changes (16S rRNA, and metagenomic sequencing). The lack of correlation between ODP genes and transcripts demonstrates that transcriptional data are critical when assessing the activity of these genes. Collectively,</p><p>this evidence illustrates the robustness of our analyses compared to prior studies that used gene-based measurements.</p><p>3. Although multiple oxalate-degrading microbes have been identified, as the reviewer pointed out, the relative importance of each taxon has been in debate for decades(Miller and Dearing, 2013). Therefore, there have been both academic and commercial efforts using several other bacteria to alleviate oxalate toxicity (Cho, Gebhart, Furrow, and Lulich, 2015; Ellis, Shaw, Jackson, Daniel, and Knight, 2015; Lieske, 2017; Miller, Choy, Penniston, and Lange, 2019; Ticinesi, Nouvenne, and Meschi, 2019). We now provide clear evidence that demonstrates the dominant role of <italic>O. formigenes</italic> in oxalate degradation within the human microbiota. Moreover, we demonstrate potential clinical indications (e.g. Crohn’s disease of the ileocolonic phenotype, and Ulcerative colitis) when <italic>O. formigenes</italic> is lost.</p><disp-quote content-type="editor-comment"><p>Entirely Of the most novel findings of the study are the inverse correlation between Of ODP gene expression and oxalate levels in IBD. This raises interesting questions whether dysfunction in Of ODP gene expression may lead to increased gut oxalate in IBD but not healthy guts. Furthermore, why would Of not express these genes in these situations?</p></disp-quote><p>We thank the reviewer for this comment. Indeed, our findings indicate for the first time that microbiota-based oxalate degradation is significantly associated with the elevated fecal oxalate levels in IBD patients. The ODP of <italic>O. formigenes</italic>, which was the dominating ODPtranscribing microbe in health, was detected at significantly lower levels in IBD patients. The biological nature of <italic>O. formigenes</italic> as an oxalate autotroph (Cornick and Allison, 1996), requires that it continually transcribe ODP for both carbon source and for energy, leading to ATP production (Cornick and Allison, 1996). Therefore, the lack of <italic>O. formigenes</italic> ODP transcription most likely indicates its absence in IBD patients. Previous studies have demonstrated its loss of colonization is associated with antibiotic use, which is common in IBD patients (Liu et al., 2017). Our study now raises testable hypotheses that common treatments including antibiotics and other medications with antibacterial activities have caused the loss of these bacteria in IBD patients.</p><disp-quote content-type="editor-comment"><p>In general, I am under impressed by this manuscript. The description of ODP pathways in metagenomes and the expression by Oxalobacter formigens and <italic>E. coli</italic> is not particularly unexpected. The inverse relationship between oxalate levels in IBD and Oxalobacter expression is interesting but again I can't equate this finding with the level of findings of this journal.</p></disp-quote><p>We appreciate the reviewer’s time and comments. We have provided evidence (above) of how our study has provided novel insights in this area in both health and disease, and have included new data from a mouse model supporting the important in vivo role of <italic>O. formigenes</italic> in oxalate homeostasis (new Figure 6 in on page 39).</p><p>References:</p><p>Binder, H. J. (1974). Intestinal oxalate absorption. <italic>Gastroenterology, 67</italic>(3), 441-446.</p><p>Canales, B. K., and Hatch, M. (2017). Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria. <italic>Surg Obes Relat Dis, 13</italic>(7), 1152-1157. doi:10.1016/j.soard.2017.03.014</p><p>Cho, J. G., Gebhart, C. J., Furrow, E., and Lulich, J. P. (2015). Assessment of in vitro oxalate degradation by <italic>Lactobacillus</italic> species cultured from veterinary probiotics. <italic>Am J Vet Res, 76</italic>(9), 801-806. doi:10.2460/ajvr.76.9.801</p><p>Cornick, N. A., and Allison, M. J. (1996). Assimilation of oxalate, acetate, and CO2 by Oxalobacter formigenes. <italic>Can J Microbiol, 42</italic>(11), 1081-1086. doi:10.1139/m96-138</p><p>Cury, D. B., Moss, A. C., and Schor, N. (2013). Nephrolithiasis in patients with inflammatory bowel disease in the community. <italic>Int J Nephrol Renovasc Dis, 6</italic>, 139-142. doi:10.2147/IJNRD.S45466</p><p>Ellis, M. L., Shaw, K. J., Jackson, S. B., Daniel, S. L., and Knight, J. (2015). Analysis of Commercial Kidney Stone Probiotic Supplements. <italic>Urology, 85</italic>(3), 517-521. doi:https://doi.org/10.1016/j.urology.2014.11.013</p><p>Knauf, F., Ko, N., Jiang, Z., Robertson, W. G., Van Itallie, C. M., Anderson, J. M., and Aronson, P. S. (2011). Net intestinal transport of oxalate reflects passive absorption and SLC26A6-mediated secretion. <italic>J Am Soc Nephrol, 22</italic>(12), 2247-2255. doi:10.1681/ASN.2011040433</p><p>Lieske, J. C. (2017). Probiotics for prevention of urinary stones. <italic>Annals of translational medicine, 5</italic>(2), 29-29. doi:10.21037/atm.2016.11.86</p><p>Liu, M., Koh, H., Kurtz, Z. D., Battaglia, T., PeBenito, A., Li, H.,... Blaser, M. J. (2017). Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project. <italic>Microbiome, 5</italic>(1), 108. doi:10.1186/s40168-017-0316-0</p><p>Miller, A. W., Choy, D., Penniston, K. L., and Lange, D. (2019). Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis. <italic>Kidney Int, 96</italic>(1), 180-188. doi:10.1016/j.kint.2019.02.012</p><p>Miller, A. W., and Dearing, D. (2013). The metabolic and ecological interactions of oxalate-degrading bacteria in the Mammalian gut. <italic>Pathogens, 2</italic>(4), 636-652. doi:10.3390/pathogens2040636</p><p>Saunders, D. R., Sillery, J., and McDonald, G. B. (1975). Regional differences in oxalate absorption by rat intestine: evidence for excessive absorption by the colon in steatorrhoea. <italic>Gut, 16</italic>(7), 543-548. doi:10.1136/gut.16.7.543</p><p>Ticinesi, A., Nouvenne, A., and Meschi, T. (2019). Gut microbiome and kidney stone disease: not just an Oxalobacter story. <italic>Kidney Int, 96</italic>(1), 25-27. doi:https://doi.org/10.1016/j.kint.2019.03.020</p></body></sub-article></article>